Archive for May, 2020

A perfect mix of quantitative & qualitative Gene Therapy for Age-related Macular Degenerationmarket information highlighting developments, industry challenges that competitors are facing along with gaps and opportunities available and would trend in Gene Therapy for Age-related Macular Degenerationmarket. The study bridges the historical data from 2014 to 2019 and estimated until 2025.

The Gene Therapy for Age-related Macular DegenerationMarket report also provides the market impact and new opportunities created due to the COVID19/CORONA Virus Catastrophe The total market is further divided by company, by country, and by application/types for the competitive landscape analysis. The report then estimates 2020-2025 market development trends of Gene Therapy for Age-related Macular DegenerationIndustry.

Downlaod Sample ToC to understand the CORONA Virus/COVID19 impact and be smart in redefining business strategies. https://inforgrowth.com/CovidImpact-Request/6321856/gene-therapy-for-age-related-macular-degeneration-

The Top players are RetroSense Therapeutics, REGENXBIO, AGTC, .

Market Segmentation:

Gene Therapy for Age-related Macular Degeneration Market is analyzed by types like Subretinal, Intravitreal, Unspecified

On the basis of the end users/applications, Monotherapy, Combination Therapy

Download Free Sample PDF along with few company profileshttps://inforgrowth.com/sample-request/6321856/gene-therapy-for-age-related-macular-degeneration-

Be the first to knock the door showing the potential that Gene Therapy for Age-related Macular Degenerationmarket is holding in it. Uncover the Gaps and Opportunities to derive the most relevant insights from our research document to gain market size.

A major chunk of this Global Gene Therapy for Age-related Macular DegenerationMarket research report is talking about some significant approaches for enhancing the performance of the companies. Marketing strategies and different channels have been listed here. Collectively, it gives more focus on changing rules, regulations, and policies of governments. It will help to both established and new startups of the market.

The study objectives of this report are:To analyze global Gene Therapy for Age-related Macular Degenerationstatus, future forecast, growth opportunity, key market, and key players.To present the Gene Therapy for Age-related Macular Degenerationdevelopment in the United States, Europe, and China.To strategically profile the key players and comprehensively analyze their development plan and strategies.To define, describe and forecast the market by product type, market, and key regions.

Get Special Discount Up To 50%, https://inforgrowth.com/discount/6321856/gene-therapy-for-age-related-macular-degeneration-

Major Points from Table of Contents

1 Gene Therapy for Age-related Macular Degeneration Gene Therapy for Age-related Macular Degeneration Market Overview2 Gene Therapy for Age-related Macular Degeneration Market Competition by Manufacturers3 Production Capacity by Region4 Global Gene Therapy for Age-related Macular Degeneration Market by Regions5 Production, Revenue, Price Trend by Type6 Global Gene Therapy for Age-related Macular Degeneration Market Analysis by Application7 Company Profiles and Key Figures in Gene Therapy for Age-related Macular Degeneration Business8 Gene Therapy for Age-related Macular Degeneration Manufacturing Cost Analysis9 Marketing Channel, Distributors and Customers10 Market Dynamics11 Production and Supply Forecast12 Consumption and Demand Forecast13 Forecast by Type and by Application (2021-2026)14 Research Finding and Conclusion15 Methodology and Data Source.

ENQUIRE MORE ABOUT THIS REPORT AT https://inforgrowth.com/enquiry/6321856/gene-therapy-for-age-related-macular-degeneration-

FOR ALL YOUR RESEARCH NEEDS, REACH OUT TO US AT:Address: 6400 Village Pkwy suite # 104, Dublin, CA 94568, USAContact Name: Rohan S.Email:[emailprotected]Phone: +1-909-329-2808UK: +44 (203) 743 1898Website: http://www.inforgrowth.com

Go here to read the rest:
Latest News 2020: Gene Therapy for Age-related Macular Degeneration Market by Coronavirus-COVID19 Impact Analysis With Top Manufacturers Analysis |...

MINNEAPOLIS & EL SEGUNDO, Calif.--(BUSINESS WIRE)--Be The Match BioTherapies, an organization offering solutions for companies developing and commercializing cell and gene therapies, and NantKwest (Nasdaq: NK), a next generation, clinical-stage immunotherapy company focused on harnessing the unique power of the immune system using natural killer (NK) cells to treat cancer and infectious diseases, today announced an agreement through which Be The Match BioTherapies is providing donor material for a NantKwest Phase 1b clinical trial to address acute respiratory distress syndrome (ARDS), one of the primary causes of COVID-19 deaths.

The agreement combines Be The Match BioTherapies ability to provide high-quality cellular source material from the worlds largest registry of volunteer donors with NantKwests capabilities in manufacturing off-the-shelf cell therapies. NantKwests allogeneic cell therapy is derived from human bone marrow and designed to treat the ARDS that results from severe COVID-19 cases. The therapy, called BM-Allo.MSC, uses mesenchymal stem cells (MSCs), multipotent progenitor cells known to have immunomodulatory properties, to reduce the lung inflammation associated with ARDS. Similar work in Europe with allogeneic MSC products in patients with COVID-19 and ARDS has demonstrated safety and efficacy in reducing inflammatory processes.

NantKwest recently announced FDA authorization of its investigational new drug (IND) application for BM-Allo.MSC and is moving rapidly to initiate a Phase 1b trial in patients with severe COVID-19. To expedite trial initiation, Be The Match BioTherapies is providing cryopreserved donor stem cell material from the Be The Match BioBank, a program of the National Marrow Donor Program/Be The Match. The accelerated access to material, combined with NantKwests scalable manufacturing processes, will allow for rapid distribution of BM-Allo.MSC to patients in need.

There is an immediate need for COVID-19 therapies across all stages of the disease, including for patients with ARDS, which is one of the most critical conditions caused by COVID-19, said Patrick Soon-Shiong, MD, Chairman and Chief Executive Officer of NantKwest. Thanks to the quality source material provided by Be The Match BioTherapies, we are prepared to rapidly scale manufacturing of this much-needed therapy, potentially saving numerous patients lives.

Through our teams unparalleled ability to identify, source and deliver high-quality donor material we have the opportunity to support the advancement of a cell therapy with potential to change the world. We are proud to partner with NantKwest to support our mission to save lives through cellular therapy and continue to make a difference for critically ill patients around the globe, said Chris McClain, Senior Vice President, Sales and New Business Development at Be The Match BioTherapies.

About Be The Match BioTherapies

Be The Match BioTherapies is the only cell and gene therapy solutions provider with customizable services to support the end-to-end cell therapy supply chain. Backed by the industry-leading experience of the National Marrow Donor Program (NMDP)/Be The Match, and a research partnership with the CIBMTR (Center for International Blood and Marrow Transplant Research), the organization designs solutions that advance the development of cell and gene therapies across the globe.

Be The Match BioTherapies is dedicated to accelerating patient access to life-saving cell and gene therapies by providing high-quality cellular source material from the Be The Match Registry, the worlds largest and most diverse registry of more than 22 million potential blood stem cell donors. Through established relationships with apheresis, marrow collection and transplant centers worldwide, the organization develops, onboards, trains and manages expansive collection networks to advance cell therapies. Be The Match BioTherapies uses proven infrastructure consisting of regulatory compliance and managed logistics experts, as well as cell therapy supply chain case managers to successfully transport and deliver regulatory compliant life-saving therapies across the globe. Through the CIBMTR, Be The Match BioTherapies extends services beyond the cell therapy supply chain to include long-term follow-up tracking for the first two FDA-approved CAR-T therapies.

For more information, visit http://www.BeTheMatchBioTherapies.com or follow Be The Match BioTherapies on LinkedIn or Twitter at @BTMBioTherapies.

About NantKwest

NantKwest (Nasdaq: NK) is an innovative, clinical-stage immunotherapy company focused on harnessing the power of the innate immune system to treat cancer and virally-induced infectious diseases. NantKwest is the leading producer of clinical dose forms of off-the-shelf natural killer (NK) cell therapies. The activated NK cell platform is designed to destroy cancer and virally-infected cells. The safety of these optimized, activated NK cellsas well as their activity against a broad range of cancershas been tested in Phase I clinical trials in Canada and Europe, as well as in multiple Phase I and II clinical trials in the United States. By leveraging an integrated and extensive genomics and transcriptomics discovery and development engine, together with a pipeline of multiple, clinical-stage, immuno-oncology programs, NantKwests goal is to transform medicine by delivering living drugs-in-a-bag and bringing novel NK cell-based therapies to routine clinical care. NantKwest is a member of the NantWorks ecosystem of companies. For more information, please visit http://www.nantkwest.com.

Read more from the original source:
Be The Match BioTherapies and NantKwest Announce Collaboration to Accelerate Development of Cell Therapy to Prevent COVID-19 Deaths - Business Wire

(MENAFN - eSherpa Market Reports) Global Gene Therapy Market trend report 2020 highlights the Impact of COVID-19 on Gene Therapy Market. The report defines market risks, business portfolio, market share, revenue generation, the latest research and development, and market expert perspectives. It comprises brief information about the segments, as well as insightful research on Porter's five forces analysis and SWOT analysis.

Then the market is an analysis based on top industry manufacturers, countries, product types, and key applications. based on segments by manufacturers, this report focuses on the sales, price of each type, the average price, revenue, and market share, for key manufacturers.

Get Free Sample PDF Copy (including COVID19 Impact Analysis, full TOC, Tables, and Figures) of Gene Therapy Market Report @ https://www.esherpamarketreports.com/request-sample/es-408437/?utm_source=MENAFN

Key Businesses Segmentation of Gene Therapy Market:

By Types, the Gene Therapy Market can be Splits into:

Gene Induced ImmunotherapyOncolytic VirotherapyGene TransferBy Applications, the Gene Therapy Market can be Splits into:

HospitalsDiagnostics CentersResearch InstitutesList of Top Key Players of Gene Therapy Market:

Adaptimmune, GlaxoSmithKline, Bluebird bio, Merck, Celgene, Shanghai Sunway Biotech, BioCancell, Shenzhen SiBiono GeneTech, SynerGene Therapeutics, OncoGenex Pharmaceuticals, Genelux Corporation, Cell Genesys, Advantagene, GenVec, BioCancellThe study objectives of Gene Therapy Market report are:

To research the Gene Therapy for individual growth trends and their contribution to the entire market.To analyze and study the worldwide Gene Therapy capacity, production, value, consumption, status (2014-2019) and forecast (2020-2024);To strategically profile the key players and completely analyze their growth strategies.To identify significant trends and factors affecting market growth.To define and forecast the market by type, application and region.To project the consumption of Gene Therapy submarkets, for key regions

Enquire before purchasing this report @ https://www.esherpamarketreports.com/pre-order-enquiry/es-408437?utm_source=MENAFN

The Gene Therapy Market Report has answers to all your questions such as:

What are the opportunities which will affect the expansion of the market?What is the structure of the Gene Therapy market in region 1?What are the various distribution channels adopted by market players within the Gene Therapy market?Who are the most famous players within the Gene Therapy market?What is going to be the estimation of cost and profit?

Reasons To Buy:

Market forecast for a minimum of 5 years for all the segments, sub-segments in various countries and regionsTop competitors using forecast data and also the drivers and trends shaping the market.Benchmark performance against key competitors.Strategic support in key business segments based on market valuationsAccurate and complete study of the Gene Therapy market with the help of SWOT analysis, and opportunity evaluation.

Purchase this Report with Full Access @ https://www.esherpamarketreports.com/purchase/es-408437/?utm_source=MENAFN

Gene Therapy Market TOC Covers the Following Points:

Section 1 Gene Therapy Product DefinitionSection 2 Global Gene Therapy Market Manufacturer Share and Market Overview2.1 Global Manufacturer Gene Therapy Shipments2.2 Global Manufacturer Gene Therapy Business Revenue2.3 Global Gene Therapy Market OverviewSection 3 Manufacturer Gene Therapy Business IntroductionSection 4 Global Gene Therapy Market Segmentation (Region Level)Section 5 Global Gene Therapy Market Segmentation (Product Type Level)5.1 Global Gene Therapy Market Segmentation (Product Type Level) Market Size 2014-20195.2 Different Gene Therapy Product Type Price 2014-20195.3 Global Gene Therapy Market Segmentation (Product Type Level) AnalysisSection 6 Global Gene Therapy Market Segmentation (Industry Level)6.1 Global Gene Therapy Market Segmentation (Industry Level) Market Size 2014-20196.2 Different Industry Price 2014-20196.3 Global Gene Therapy Market Segmentation (Industry Level) AnalysisSection 7 Global Gene Therapy Market Segmentation (Channel Level)7.1 Global Gene Therapy Market Segmentation (Channel Level) Sales Volume and Share 2014-20197.2 Global Gene Therapy Market Segmentation (Channel Level) AnalysisSection 8 Gene Therapy Market Forecast 2019-20248.1 Gene Therapy Segmentation Market Forecast (Region Level)8.2 Gene Therapy Segmentation Market Forecast (Product Type Level)8.3 Gene Therapy Segmentation Market Forecast (Industry Level)8.4 Gene Therapy Segmentation Market Forecast (Channel Level)Section 9 Gene Therapy Segmentation Product TypeSection 10 Gene Therapy Segmentation IndustrySection 11 Gene Therapy Cost of Production Analysis11.1 Raw Material Cost Analysis11.2 Technology Cost Analysis11.3 Labor Cost Analysis11.4 Cost Overview.And More

Contact Us:

Name: Jason George

Email:

Call : USA: +1 408 757 0510

Organization: eSherpa Market Reports

MENAFN19052020007010847ID1100186734

The rest is here:
COVID-19: RESPONDING TO THE BUSINESS IMPACTS OF Gene Therapy MARKET 2019 TRENDS, SIZE, SEGMENTS, EMERGING TECHNOLOGIES AND INDUSTRY GROWTH BY...

SEATTLE, May 19, 2020 (GLOBE NEWSWIRE) -- Increasing incidence of antimicrobial-resistance is expected to drive growth of the bacteriophage therapy market during the forecast period. For instance, according to Centers for Disease Control and Prevention (CDC), around 2 million people suffer from antibiotic-resistant infection, and at least 23,000 people die each year in the U.S.

Rising funding for research and development of bacteriophage therapies is expected to drive the market growth. For instance, in August 2018, Phagomed Biopharma Gmbh. announced that their alternative therapies to combat antibiotic-resistant bacteria, has obtained grants worth US$ 4.67 million for developing virus(phage) based therapies against bacterial infections. The grant will be used to continue pre-clinical development of three drug candidates.

Read Report Summary @ https://www.coherentmarketinsights.com/market-insight/bacteriophages-therapy-market-2752

Increasing government funding is supporting phage therapy manufacturers to develop innovative approach in order to reduce incidence of antimicrobial-resistant infections is expected to propel the market growth. For instance, in January 2016, National Institute of Allergy and Infectious Diseases (NIAID), a part of the National Institutes of Health, has awarded US$ 5 million for 24 research projects to develop non-traditional therapeutics such as bacteriophage or phage therapy and others therapies for the treatment of bacterial infections

Furthermore, increasing acquisitions and partnership agreements by players are expected to propel the market growth over the forecast period. For instance, in July 2019, Pherecydes Pharma entered a collaborative agreement with France-based, Bioaster Technology Research Institute (TRI) for microbiology and infectious diseases, to explore the use of phage therapy for treating complicated urinary tract infections. Under this collaboration, Pherecydes Pharma and Bioaster initiated PhagUTI project.

Request for Sample PDF copy @ https://www.coherentmarketinsights.com/insight/request-sample/2752

Key Market Takeaways:

Key players operating in the global bacteriophage therapy market include

Armata Pharmaceuticals, Inc., Eliava Biopreparations Ltd., Pherecydes Pharma, Intralytix, Inc., Phagelux Inc., Nextbiotics, InnoPhage, Ltd, Locus Biosciences, Inc., TechnoPhage, Eligo Bioscience SA, Phagomed Biopharma GmbH., PhagePro, Inc., Adaptive Phage Therapeutics, Inc., EnBiotix, Inc., Intodeworld, Inc., BiomX Ltd., Phi Therapeutics, Fixed-phage Ltd., Micreos BV, and ContraFect Corporation.

Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/2752

Market Segmentation:

Related Topics:

GLYCOBIOLOGY MARKET

Glycobiology involves study of structural aspects, biosynthesis, and biology of polysaccharides and how they function in an organism. Study of glycobiology has variety of application in areas such as drug discovery and development, diagnostic applications, therapeutic application, and industrial applications.

Read more @ https://www.coherentmarketinsights.com/market-insight/glycobiology-market-3639

VIRAL VECTOR AND PLASMID DNA TESTING SERVICES MARKET

Viral vectors are the best approach used in the gene therapies and therefore, testing services are the key factors for the timely development of viral vector-based therapies. Viral vector characterization plays an important role for orthogonal analytical approaches. The characterization is significant through the regulatory perspective, which include product safety, identity, purity, and potency.

Read more @ https://www.coherentmarketinsights.com/market-insight/viral-vector-and-plasmid-dna-testing-services-market-3637

GMP CELL BANKING SERVICES MARKET

GMP cell banking services is termed as the storing of cells of specific genome for the purpose of future use in a product or medicinal needs. Different types of cell lines stored in cell banks constitute of mammalian cells, microbial cells, insect cell lines, yeast cells, avian cells, and stem cells.

Read more @ https://www.coherentmarketinsights.com/market-insight/gmp-cell-banking-services-market-3634

Go here to read the rest:
Bacteriophage Therapy Market to grow at a significant rate during 2020-2027, owing to rising prevalence of antibiotic resistant infection Coherent...

DUBLIN, May 19, 2020 /PRNewswire/ -- The "Blood-Brain Barrier (BBB) Market (2nd Edition), 2020-2030: Focus on Non-Invasive Drug Delivery Technology Platforms and Therapeutics" report has been added to ResearchAndMarkets.com's offering.

Blood-Brain Barrier (BBB) Market, 2020-2030: Focus on Non-Invasive Drug Delivery Technology Platforms and Therapeutics (2nd Edition) [based on Receptor Mediated Transcytosis, Trojan Horse, and Nanoparticle based Approaches] features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of BBB penetration technologies and affiliated drugs, over the next decade. The report features an in-depth analysis, highlighting the diverse capabilities of stakeholders engaged in this domain.

One of the key objectives of the report was to estimate the existing market size and identify potential growth opportunities for BBB penetration technologies and affiliated therapeutics, over the next decade. Based on likely licensing deal structures and agreements that are expected to be inked in the foreseen future, we have provided an informed estimate of the evolution of the market for the period 2020-2030. In addition, we have provided information on (potential) sales-based revenues generated by BBB penetrant drugs that are currently in late stages of development for the treatment of different CNS disorders, based on parameters, such as target consumer segments, likely adoption rates, expected pricing and associated risk-adjustment sales opportunity.

The report also features the likely distribution of the current and forecasted opportunity across:

Market Summary and Insights

According to a study conducted by the World Health Organization (WHO), diseases that affect the central nervous system (CNS), such as Alzheimer's disease, brain cancer, multiple sclerosis. Parkinson's disease and stroke, are characterized by a significant unmet need for effective treatment options. In 2019, it was reported that nearly 1.5 billion people suffer from some form of disorder affecting the CNS across the globe. In fact, the incidence of CNS disorders is anticipated to increase by 12% by 2030. In 2019, nearly 5.8 million Americans were reported to have been diagnosed with Alzheimer's disease.

Similarly, Parkinson's disease was estimated to affect nearly one million people in America, with approximately 60,000 new patients being diagnosed every year. Further, experts believe that there is a critical relationship between recent pandemic of novel Coronavirus (COVID-19) and the cardiovascular and cerebrovascular systems. People suffering from certain CNS complications are at a relatively higher risk of COVID-19 infection due to a compromised immune system.

It is estimated that CNS disorders are responsible for a healthcare burden of nearly USD 2 trillion, in the US and Europe. Developing viable therapies against the aforementioned clinical conditions is largely complicated due to the elusive blood-brain barrier (BBB), a selectively permeable structure, which is very effective in preventing the entry of foreign substances, including drugs, into the brain. It has been reported that over 1,000 currently available / under development drugs targeting CNS disorders do not have the potential to target specific brain receptors responsible for the disease progression due to the hindrance by the BBB. Considering the serious physical, cognitive and psychosocial consequences that such indications have on patients, coupled to the alarming increase in their global prevalence, there is an urgent need for novel and effective treatment options that can cross the BBB.

Over time, extensive R&D efforts have resulted in the development of a number of versatile BBB penetration technologies. These technologies have been designed either to externally alter the permeability of the BBB or augment the BBB penetrating capabilities of compatible pharmacological interventions. As a result, presently, there is a lot of enthusiasm within the medical science community related to these technologies.

The growing interest in this field is also evident in the fact that over 1,200 modern scientific articles have been published (as observed on NCBI's PubMed portal) over the last three years alone. However, it is worth mentioning that there are currently no approved BBB penetrating drugs available in the market. Currently, this niche market is driven by technology licensing activity, with drug developers collaborating with platform providers to grow their respective therapeutic pipelines. In fact, over the last 4-5 years, there has been a marked rise in the number of new entrants in this field. We anticipate this upcoming market to witness substantial growth in the coming years.

In addition to other elements, the study includes:

In order to account for the uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry's growth.

The opinions and insights presented in this study were also influenced by discussions conducted with multiple stakeholders in this domain. The report features detailed transcripts of interviews held with the following individuals:

Key Questions Answered

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/wgim84

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/blood-brain-barrier-markets-insights-and-forecast-to-2030-by-type-of-molecule-target-disease-indications-key-contributing-technologies-leading-drug-developers-and-key-geographical-regions-301061789.html

SOURCE Research and Markets

Link:
Blood-Brain Barrier Markets Insights and Forecast to 2030 by Type of Molecule, Target Disease Indications, Key Contributing Technologies, Leading Drug...

Facts & Factors Market Research added a recent report on Cancer Gene Therapy Market By Type (Ex-vivo and In-vivo) and By Product (Viral Vectors, Non-viral Vectors, and Others): Global Industry Outlook, Market Size, Business Intelligence, Consumer Preferences, Statistical Surveys, Comprehensive Analysis, Historical Developments, Current Trends, and Forecasts, 20202026 to its research database. The Cancer Gene Therapy Market research report is an output of a brief assessment and an extensive analysis of practical data collected from the global industry.

This specialized and expertise oriented industry research report scrutinizes the technical and commercial business outlook of the Cancer Gene Therapy industry. The report analyzes and declares the historical and current trends analysis of the Cancer Gene Therapy industry and subsequently recommends the projected trends anticipated to be observed in the Cancer Gene Therapy market during the upcoming years.

The Cancer Gene Therapy market report analyzes and notifies the industry statistics at the global as well as regional and country levels to acquire a thorough perspective of the entire Cancer Gene Therapymarket. The historical and past insights are provided for FY 2016 to FY 2019 whereas projected trends are delivered for FY 2020 to FY 2026. The quantitative and numerical data is represented in terms of value from FY 2016 2026.

The quantitative data is further underlined and reinforced by comprehensive qualitative data which comprises various across-the-board market dynamics. The rationales which directly or indirectly impact the Cancer Gene Therapy industry are exemplified through parameters such as growth drivers, restraints, challenges, and opportunities among other impacting factors.

Request an Exclusive Free Sample Report of Cancer Gene Therapy Market: https://www.fnfresearch.com/sample/cancer-gene-therapy-market-by-type-ex-vivo-898

Our Every Free Sample Includes:

A research report overview, TOC, list of tables and figures, an overview of major market players and key regions included.

Some of Top Market Players Analysis Included in this Report:

Vigene Biosciences, Sirion Biotech, Bluebird bio, Cellectis, Ziopharm, Cobra, Uniqure, Finvector, Sarepta Therapeutics

The Market Player Analysis based on some of below Factors:

Inquire more about this report before purchase @ https://www.fnfresearch.com/inquiry/cancer-gene-therapy-market-by-type-ex-vivo-898

This research report provides forecasts in terms of CAGR, and Y-O-Y growth. This helps to understand the overall market and to recognize the growth opportunities in the global Cancer Gene Therapy Market. The report also includes a detailed profile and information of all the major market players currently active in the global Cancer Gene Therapy Market. The companies covered in the report can be evaluated based on their latest developments, financial and business overview, product portfolio, key trends in the market, long-term and short-term business strategies by the companies to stay competitive in the market.

The global Cancer Gene Therapy Market size & trends are classified based on the types of products, application segments, and end-user. Each segment expansion is assessed together with the estimation of their growth in the upcoming period. The related data and statistics collected from the regulatory organizations are portrayed in the Cancer Gene Therapy Market report to assess the growth of each segment.

The global Cancer Gene Therapy Market size & trends are classified based on the types of products, application segments, and end-user. Each segment expansion is assessed together with the estimation of their growth in the upcoming period. The related data and statistics collected from the regulatory organizations are portrayed in the Cancer Gene Therapy Market report to assess the growth of each segment.

Request Customized Copy of Report @ https://www.fnfresearch.com/customization/cancer-gene-therapy-market-by-type-ex-vivo-898

(We customize your report according to your research need. Ask our sales team for report customization).

Available Customization Options:

The Cancer Gene Therapy Market can be customized to the country level or any other market segment. Besides this, Report understands that you may have your own business need, hence we also provide fully customized solutions to clients.

KEY REPORT POINTERS & HIGHLIGHTS:

To Know More about Discount on Specific Report, Kindly Mail us at [[emailprotected]]with Your requirement. We will send you a quote and discount offer, if available.

About Us:

Facts & Factors is a leading market research company and offers customized research reports and consulting services. Facts & Factors aims at management consulting, industry chain research, and advanced research to assist our clients by providing planned revenue model for their business. Our report and services are used by prestigious academic institutions, start-ups, and companies globally to understand the international and regional business background. Our wide-ranging database offers statistics and detailed analysis of different industries worldwide that help the clients in achieving sustainable progress. The well-organized reports help clients in developing strategies and making informed business decisions.

Contact Us:

Facts & Factors

Global Headquarters

Level 8, International Finance Center, Tower 2,

8 Century Avenue, Shanghai,

Postal 200120, China

Tel: +8621 80360450

E-Mail: [emailprotected]

Web:https://www.fnfresearch.com

Excerpt from:
The Impact of Coronavirus on The Cancer Gene Therapy Market 2020 Projected to Witness Robust Development by 2026 3w Market News Reports - 3rd Watch...

A new study on the Gene Therapy market provides a detailed overview of the demands and consumptions of various products/services associated with the growth dynamics of the market during the historical period 2015 2019. The in-depth market estimation of various opportunities in the segments is expressed in volumes and revenues during the forecast period 2020 2026. The insights and analytics on the Gene Therapy market span several pages. These are covered in numerous sections, including, drivers and restraints, challenges and opportunities, regional segmentation and opportunity assessment, end-use/application prospects analysis, and competitive landscape assessment.Despite the ongoing issues, the worldwide revenue of gene therapy market will surpass US$ 5 Bn by 2026, exhibiting a stellar growth rate.

Key stakeholders in the Gene Therapy market including industry players, policymakers, and investors in various countries have been continuously realigning their strategies and approaches to implement them in order to tap into new opportunities. Many in recent months have overhauled their strategies to remain agile in the backdrop of worldwide disruptions caused by the COVID-19 pandemic.

Request to View Sample of Research Report @ https://www.factmr.com/connectus/sample?flag=S&rep_id=4648

The study also offers scrutiny of the changing government policies amid COVID-19 disruptions. Policymakers in developing and developed nations are framing new regulations to meet the continuing macrocosmic shocks by COVID-19 pandemic. The authors of the report have taken into account the impact analysis of the pandemic, and have elaborated on the trends that will be crucial to the upcoming competitive landscape. New entrants, as well as established players who want to emerge as leaders in the post-COVID era, are taking the impact analysis seriously.

The following insights and evaluations are worth knowing for any market participant, helping them in ascertaining the prevailing dynamics and the future trajectories of the Gene Therapy market. They are a part of the estimations of the opportunities in various segments.

Some of the insights and market estimations that make this study unique in approach and effective in guiding stakeholders in understanding the growth dynamics. The study provides:

The regional segmentation of the Gene Therapy market is done as follows:

On the basis of product types, the Gene Therapy market report offers insight into major adoption trends for the following segments:

Key end-users covered in the study include:

Companies profiled in the report are:

To Know More Information about This Report, Ask The Analyst @ https://www.factmr.com/connectus/sample?flag=AE&rep_id=4648

How can Fact.MR Make Difference?

Contact:

Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A,

Jumeirah Lakes Towers, Dubai, United Arab Emirates

MARKET ACCESS DMCC Initiative

Email: sales@factmr.com

Web: https://www.factmr.com/

Press Release- https://www.factmr.com/media-release/1409/global-gene-therapy-market

Read this article:
Gene Therapy Market Revenue Status & Forecast Report 2020 to 2026 - The Cloud Tribune

Review highlights the history, progress and potential of cells of the innate immune system that can be harnessed for treatment of cancer

LA JOLLA, Calif., May 19, 2020 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the Company), a clinical-stage immunology company focused on developing treatments that harness the patients innate immune system to fight disease, announced publication of a review article: Killers at the crossroads: The use of innate immune cells in adoptive cellular therapy of cancer in the journal Stem Cells Translational Medicine by May Sabry, PhD and Professor Mark Lowdell, PhD, co-founder and Chief Scientific Officer of INmune Bio, past vice-president (Europe) of the International Society of Cell & Gene Therapy (ISCT) and faculty professor at University College London. The article reviews the potential of harnessing cells of the innate immune system to treat cancer.

I was delighted to be invited to review the exciting array of clinical trials of innate immunotherapies for the specialized translational scientists who read SCTM. The innate immune response is so often overlooked as a therapeutic tool, but its conserved presence throughout evolution suggests that it is the most important mediator of tumor immune surveillance, said Prof Lowdell.

This publication is one of the first to comprehensively review clinical trials of the common innate immune effector cells. It highlights the breadth of innate immunotherapy options and the global interest in harnessing this side of the immune system. Prof. Lowdell has been a leader in identifying how cancer evades innate immune surveillance by NK cells and how to overcome those resistance mechanisms to allow NK cells to attack the tumor.

Of all the innate immune effectors in trial, NK cells have been, and remain, at the forefront. More is understood about the NK:tumour cell interaction than any of the other cells and many of the mechanisms which impair function are understood. Uniquely among the innate immune effector cells, NK cells have been shown to be effective without ex vivo manipulation but with in vivo activation with monoclonal antibodies such as Rituximab and Herceptin and with cytokines such as IL-2 and, more recently, IL-15 derivatives, said Prof Lowdell. In this vein, INmune Bio has developed INKmune, an off-the-shelf therapy to activate a cancer patients NK cells in vivo to attack their own cancer cells. INKmune is scheduled to enter clinical trials in the next 12 months in the treatment of patients with ovarian cancer and high-risk MDS. To learn more about INKmune, please visit our website at http://www.inmunebio.com.

About INmune Bio, Inc.

INmune Bio, Inc. is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has two product platforms. The DN-TNF product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and mechanistic target of many diseases. DN-TNF is currently being developed for COVID-19 complications (Quellor), cancer (INB03), Alzheimers (XPro595), and NASH (LIVNate). The Natural Killer Cell Priming Platform includes INKmune aimed at priming the patients NK cells to eliminate minimal residual disease in patients with cancer. INmune Bios product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors and chronic inflammation. To learn more, please visitwww.inmunebio.com.

Forward Looking Statements

Clinical trials are in early stages and there is no assurance that any specific outcome will be achieved. Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. INB03, XPro1595, LIVNate, DN-TNF and INKmune are still in clinical trials and have not been approved and there cannot be any assurance that they will be approved or that any specific results will be achieved. Our two platforms are beginning clinical trials and there cannot be any assurance of the success of these trials. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Companys ability to produce more drug for clinical trials; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Companys business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Companys filings with the Securities and Exchange Commission, including the Companys Annual Report on Form 10-K, the Companys Quarterly Reports on Form 10-Q and the Companys Current Reports on Form 8-K. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.

INmune Bio Contact:David Moss, CFO (858) 964-3720DMoss@INmuneBio.com

Investor Contact:James Carbonara (646) 755-7412James@haydenir.com

Read more from the original source:
Killers at the Crossroad A Published Review of Innate Immune Cell Potential in Treatment of Cancers Published by Co-Founder and CSO of INmune Bio,...

North America, Europe, China, Japan, Rest of the World,May 2020, The Viral Vector & Plasmid DNA Manufacturing Market research report includes an in-sight study of the keyViral Vector & Plasmid DNA Manufacturing Market Researchprominent players along with the company profiles and planning adopted by them. This helps the buyer of the Viral Vector & Plasmid DNA Manufacturing report to gain a clear view of the competitive landscape and accordingly plan Viral Vector & Plasmid DNA Manufacturing market strategies. An isolated section with top key players is provided in the report, which provides a complete analysis of price, gross, revenue(Mn), Viral Vector & Plasmid DNA Manufacturing specifications, and company profiles. The Viral Vector & Plasmid DNA Manufacturing study is segmented by Module Type, Test Type, And Region.

The market size section gives the Viral Vector & Plasmid DNA Manufacturing market revenue, covering both the historic growth of the market and the forecasting of the future. Moreover, the report covers a host of company profiles, who are making a mark in the industry or have the potential to do so. The profiling of the players includes their market size, key product launches, information regarding the strategies they employ, and others. The report identifies the total market sales generated by a particular firm over a period of time. Industry experts calculate share by taking into account the product sales over a period and then dividing it by the overall sales of the Viral Vector & Plasmid DNA Manufacturing industry over a defined period.

Download Full PDF Sample Copy of Report:jcmarketresearch.com/report-details/11639/sample

The research covers the current market size of the Viral Vector & Plasmid DNA Manufacturing Market Researchand its growth rates based on 5 year history data. It also covers various types of segmentation such as by geography North America, Europe, Asia-Pacific etc., by product type Viral Vector & Plasmid DNA Manufacturing Market Research, by applications Biopharmaceutical Companies Research Institutes Main Ain overall market. The in-depth information by segments of Viral Vector & Plasmid DNA Manufacturing market helps monitor performance & make critical decisions for growth and profitability. It provides information on trends and developments, focuses on markets and materials, capacities, technologies, CAPEX cycle and the changing structure of the Viral Vector & Plasmid DNA Manufacturing Market Research.

This study also contains company profiling, product picture and specifications, sales, market share and contact information of various international, regional, and local vendors of Viral Vector & Plasmid DNA Manufacturing Market Research. The market competition is constantly growing higher with the rise in technological innovation and M&A activities in the industry. Moreover, many local and regional vendors are offering specific application products for varied end-users. The new vendor entrants in the market are finding it hard to compete with the international vendors based on quality, reliability, and innovations in technology.

Global Viral Vector & Plasmid DNA Manufacturing (Thousands Units) and Revenue (Million USD) Market Split by Product Type such as Adenovirus Retrovirus Plasmid DNA Others M

The research study is segmented by Application such as Laboratory, Industrial Use, Public Services & Others with historical and projected market share and compounded annual growth rate.Global Viral Vector & Plasmid DNA Manufacturing (Thousands Units) by Regions (2019-2025)

Geographically,this report is segmented into several key Regions, with production, consumption, revenue (million USD), and market share and growth rate of Viral Vector & Plasmid DNA Manufacturing in these regions, from 2012 to 2022 (forecast), covering

Get Exclusive Discount:jcmarketresearch.com/report-details/11639/discount

There are 15 Chapters to display theViral Vector & Plasmid DNA Manufacturing Market Research.

Chapter 1, to describe Definition, Specifications and Classification of Viral Vector & Plasmid DNA Manufacturing , Applications of Viral Vector & Plasmid DNA Manufacturing , Market Segment by Regions;

Chapter 2, to analyze the Manufacturing Cost Structure, Raw Material and Suppliers, Manufacturing Process, Industry Chain Structure;

Chapter 3, to display the Technical Data and Manufacturing Plants Analysis ofViral Vector & Plasmid DNA Manufacturing, Capacity and Commercial Production Date, Manufacturing Plants Distribution, R&D Status and Technology Source, Raw Materials Sources Analysis;

Chapter 4, to show the Overall Market Analysis, Capacity Analysis (Company Segment), Sales Analysis (Company Segment), Sales Price Analysis by Merck uniQure The Cell and Gene Therapy Catapult Waisman Biomanufacturing Addgene Creative Biogene Novasep Cobra Biologics Aldevron;

Chapter 5 and 6, to show the Regional Market Analysis that includes North America, Europe, Asia-Pacific etc.,Viral Vector & Plasmid DNA ManufacturingSegment Market Analysis Adenovirus Retrovirus Plasmid DNA Others M;

Chapter 7 and 8, to analyze theViral Vector & Plasmid DNA ManufacturingSegment Market Analysis (by Application) Major Manufacturers Analysis ofViral Vector & Plasmid DNA Manufacturing;Merck uniQure The Cell and Gene Therapy Catapult Waisman Biomanufacturing Addgene Creative Biogene Novasep Cobra Biologics Aldevron

Chapter 9, Market Trend Analysis, Regional Market Trend, Market Trend by Product Type Adenovirus Retrovirus Plasmid DNA Others M, Market Trend by Application Biopharmaceutical Companies Research Institutes Main A;

Chapter 10, Regional Marketing Type Analysis, International Trade Type Analysis, Supply Chain Analysis;

Chapter 11, to analyze the Consumers Analysis ofViral Vector & Plasmid DNA Manufacturing;

Chapter 12, to describeViral Vector & Plasmid DNA ManufacturingResearch Findings and Conclusion, Appendix, methodology and data source;

Chapter 13, 14 and 15, to describeViral Vector & Plasmid DNA Manufacturingsales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source.

Enquiry before Buying The full report @:jcmarketresearch.com/report-details/11639/enquiry

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

About Author:JCMR global research and market intelligence consulting organization is uniquely positioned to not only identify growth opportunities but to also empower and inspire you to create visionary growth strategies for futures, enabled by our extraordinary depth and breadth of thought leadership, research, tools, events and experience that assist you for making goals into a reality. Our understanding of the interplay between industry convergence, Mega Trends, technologies and market trends provides our clients with new business models and expansion opportunities. We are focused on identifying the Accurate Forecast in every industry we cover so our clients can reap the benefits of being early market entrants and can accomplish their Goals & Objectives.

Contact Us:JCMARKETRESEARCHJay (Marketing Manager)Phone:+1 (925) 478-7203Email:[emailprotected]

More:
Viral Vector & Plasmid DNA Manufacturing Market Rising Growth With Keyplayer: Merck uniQure The Cell and Gene Therapy Catapult Waisman...

Global Viral Clearance Market is expected to rise from its initial estimated value of USD 517million in 2016 to an estimated value of USD 2457 million by 2026, registering a CAGR of 21.50% in the forecast period of 2016-2026. Increasing investment on R&D is driving the growth of this market.Some of the major players operating in global viral clearance market areInternational, Inc., Lonza, Sigma-Aldrich Co., Wuxi Pharmatech (Cayman) Inc., Merck & Co., Thermo Fisher Scientific Inc., Texcell, BSL Bioservice, Avance Biosciences, SGS SA, Eurofins Scientific, General Electric, Danaher, Sartorius AG, Agilent Technologies, Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd, Pfizer Inc., Hospitech, CSL Behring, Illumina, Inc., Eppendorf AG, PromoCell GmbH, HiMedia Laboratories, BD, Biospherix, Ltd, , and Novogene Corporation among others

Get Sample Report + All Related Graphs & Charts @http://databridgemarketresearch.com/request-a-sample/?dbmr=global-viral-clearance-market

Competitive Analysis:

Global viral clearance market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of viral clearance market for Global, Europe, North America, Asia Pacific, South America, Middle East & Africa.

Global Viral Clearance Market By Method (Viral Detection Method, Viral Removal, Viral Inactivation), Application (Vaccines and Therapeutics, Blood and Blood Products, Cellular and Gene Therapy Products, Tissue and Tissue Products, Stem Cell Products), End-User (Pharmaceutical and Biotechnology Companies, Contract Research Organizations, Academic Research Institutes), Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa) Industry Trends and Forecast to 2026

Market Definition:

Viral clearance is stated as the removal of contaminated viral by chromatography technique. The development process for monoclonal antibodies, blood derived product , glycoprotein and recombinant protein. To ensure that therapeutic drugs derived from certain sources are fully rid of any viral contamination, these protein solutions undergo viral clearance to inactivate or remove viral materials.

Market Drivers

Market Restraints

Grab Your Report at an Impressive Discount! Please click[emailprotected]https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-viral-clearance-market

Segementation: Global Viral Clearance Market

By Method

By Application

By End User

By Geography

Key Developments in the Market:

Reasons to Purchase this Report

Key Insights in the report:

Note: If you have any special requirements, please let us know and we will offer you the report as you want.

About Data Bridge Market Research:

Data Bridge Market Researchset forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email:[emailprotected]

See the original post:
Global Viral Clearance Market is Thriving with Rising Latest Trends by 2027 | Top Players- International, Inc., Lonza, Sigma-Aldrich Co., Wuxi...

Detailed Study on the Global Gene Therapy Market

A recent market study throws light on some of the leading factors that are likely to influence the growth of the Gene Therapy market in the upcoming decade. The well-researched market study touches upon the growth potential of various budding market players in the current Gene Therapy market landscape. Moreover, established players, stakeholders, and investors can leverage the data in the report to formulate effective growth strategies.

As per the report, the Gene Therapy market is forecasted to reach a value of ~US$XX by the end of 2029 and grow at a CAGR of ~XX% through the forecast period (2019-2029). The key dynamics of the Gene Therapy market including the drivers, restraints, opportunities, and trends are thoroughly analyzed in the presented report.

Get Free Sample PDF (including COVID19 Impact Analysis, full TOC, Tables and Figures) of Market Report @ https://www.marketresearchhub.com/enquiry.php?type=S&repid=2653033&source=atm

The Research Aims to Addresses the Following Doubts Pertaining to the Gene Therapy Market

The report on the Gene Therapy market provides a birds eye view of the current proceeding within the Gene Therapy market. Further, the report also takes into account the impact of the novel COVID-19 pandemic on the Gene Therapy market and offers a clear assessment of the projected market fluctuations during the forecast period. The different factors that are likely to impact the overall dynamics of the Gene Therapy market over the forecast period (2019-2029) including the current trends, growth opportunities, restraining factors, and more are discussed in detail in the market study.

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.marketresearchhub.com/enquiry.php?type=E&repid=2653033&source=atm

Gene Therapy Market Segmentation

Competitive Landscape

The competitive landscape section of the report elaborates on the recent developments and innovations introduced by prominent players in the Gene Therapy market. The growth potential, revenue growth, product range, and pricing strategies of each market player in inspected in the report with precision.

End-use Industry Assessment

The report segments the Gene Therapy market on the basis of end-use industry and offers a detailed understanding of the supply-demand ratio and consumption pattern of the Gene Therapy in each end-use industry.

Regional and Country-level AnalysisThe report offers an exhaustive geographical analysis of the global Gene Therapy market, covering important regions, viz, North America, Europe, China, Japan, Southeast Asia, India and Central & South America. It also covers key countries (regions), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, UAE, etc.The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by each application segment in terms of revenue for the period 2015-2026.Competition AnalysisIn the competitive analysis section of the report, leading as well as prominent players of the global Gene Therapy market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Gene Therapy market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Gene Therapy market.The following players are covered in this report:Bluebird BioSangamoSpark TherapeuticsDimension TherapeuticsAvalanche BioCelladonVical Inc.AdvantageneGene Therapy Breakdown Data by TypeEx vivoIn VivoGene Therapy Breakdown Data by ApplicationCancerMonogenicInfectious diseaseCardiovascular diseaseOther

You can Buy This Report from Here @ https://www.marketresearchhub.com/checkout?rep_id=2653033&licType=S&source=atm

Essential Findings of the Gene Therapy Market Report:

See the original post here:
Coronavirus' business impact: Gene Therapy Market 2019 By Advancements, Application, Challenges, Trends, Top Key Players, Growth & Forecast Till...

Global Antiaging Products and Services Market analysis report is a historical overview and all-inclusive study on the current & future market of the Healthcare industry. This market study has been analyzed and takes into account the CAGR of the market, valuation, volume, revenue including historical and forecast, sales (current and future), and other significant factors related to the global market. Antiaging Products and Services Market business document puts forward an in-depth assessment of each crucial aspect of the worldwide market that relates to the market size, market share, market growth factor, key vendors, revenue, top regions, industry trends, product demand, sales volume, capacity, cost structure & expansion in the market.

Request for Sample Copy or PDF Herehttps://www.databridgemarketresearch.com/request-a-sample?dbmr=global-antiaging-products-and-services-market

Theglobal antiaging products and services marketis expected to reach USD 859.11 billion by 2025, from USD 347.58 billion in 2017 growing at a CAGR of 11.8% during the forecast period of 2018 to 2025. The upcoming market report contains data for historic year2016, the base year of calculation is 2017 and the forecast period is 2018 to 2025.

Some of the major players operating in the globalantiaging products and services marketareChanel SA, GlaxoSmithKline Plc, Allergan Inc, Neutrogena Corporation, Procter & Gamble, Elizabeth Arden Inc, Johnson & Johnson, Orlane SA, Revlon Inc, Novartis International AG, Unilever PLC, Avon Products Inc, Woodridge Labs Inc, Beiersdorf, LOral SA, Merck & Company Inc, Christian Dior, Valeant Pharmaceuticals International, NeoStrata Company Inc, Bayer Schering Pharma AG, F. Hoffmann-La Roche Ltd among others.

Market Definition:Global Antiaging Products and Services Market

As the skin ages, it loses its natural elasticity and becomes thinner, more fragile and laxer, taking on a wrinkled appearance. In modern society, there is a great increase in the search for eternal youth and an insatiable appetite for methods which could turn back the clock. This has triggered an explosion in the antiaging industry. In addition, technological advances in medicine for the prevention and treatment of deadly diseases help to increase life expectancy.

The aging process of the skin generally has two kinds of forms: natural aging and light aging. There are various factors which directly affect intrinsic aging such as ethnicity, anatomic variations, hormonal changes, extrinsic aging, drugs, smoking and sunlight exposure. These aging conditions can be treated by the antiaging products such as UV absorbers, anti-wrinkle products, anti-stretch products, others and services and therapies. For anti-aging, the cosmetics are commercially available products that can be used to improve the appearance of the skin. People are constantly demanding for more effective products that can essentially beautify the appearance and has resulted in augmented basic science research and product development in the cosmetics industry.

According to news provided by Stempeutics Research Pvt. Ltd., in July 2015, Cipla (India) launched a new anti-aging product which uses human bio-active factors. The product was launched with a brand name Cutisera, developed by Stempeutics. This product will be used for reducing fine lines and wrinkles, lightening dark spots, evening skin tone, improving skin firmness and improving skin hydration.

Browse Detailed TOC Herehttps://www.databridgemarketresearch.com/toc?dbmr=global-antiaging-products-and-services-market&raksh

Market Segmentation:Global Antiaging Products and Services Market

The global antiaging products and services market is segmented based on product, therapies and services and geographical segments.

Based on product, the market is segmented into UV absorbers, anti-wrinkle products, anti-stretch products and others.

Based on therapies and services, the market is segmented into eye-lid surgery, abdominoplasty, hormone replacement therapy, breast augmentation, liposuction, gene therapy, injectable skin, botox, telomere based therapy, rejuvenation and dermal fillers, sclerotherapy, anti-pigmentation therapy, hair restoration services and chemical peels.

Based on geography, the market report covers data points for 28 countries across multiple geographies namely North America & South America, Europe, Asia-Pacific and, Middle East & Africa. Some of the major countries covered in this report are U.S., Canada, Germany, France, U.K., Netherlands, Switzerland, Turkey, Russia, China, India, South Korea, Japan, Australia, Singapore, Saudi Arabia, South Africa and, Brazil among others.

Major Market Drivers and Restraints:

Key Developments in the Market:

Competitive Analysis:Global Antiaging Products and Services Market

The global antiaging products and services market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of antiaging products and services market for global, Europe, North America, Asia Pacific and South America.

Reasons to Purchase this Report

Customization of the Report

Want Full Report? Enquire Herehttps://www.databridgemarketresearch.com/inquire-before-buying?dbmr=global-antiaging-products-and-services-market&raksh

About Data Bridge Market Research:

Data Bridge Market Researchis a versatile market research and consulting firm with over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Our coverage of industries include Medical Devices, Pharmaceuticals, Biotechnology, Semiconductors, Machinery, Information and Communication Technology, Automobiles and Automotive, Chemical and Material, Packaging, Food and Beverages, Cosmetics, Specialty Chemicals, Fast Moving Consumer Goods, Robotics, among many others.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude.We are content with our glorious 99.9 % client satisfying rate.

Contact Us

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475 Mail:[emailprotected]

See the article here:
Antiaging Products and Services Market Competitive Strategies and Worldwide Demand with Top Players Elizabeth Arden Inc, Johnson & Johnson,...

Vertex Pharmaceuticals (VRTX) is the $75 billion champion of cystic fibrosis (CF) who is expected to grow sales 37% this year to $5.7 billion -- after a 37% topline advance last year.

Since 2012, Vertex has developed a suite of drug treatments for CF, including the "triple threat" combo Trikafta, which was approved by the FDA in October 2019.

Cystic fibrosis is a hereditary disease that affects the lungs and digestive system. The body produces thick and sticky mucus that can clog the lungs and obstruct the pancreas. CF can be life-threatening, and people with the condition tend to have a shorter-than-normal life span, with many adults not making it to their 30th birthday.

Vertexs lead marketed products are Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor), Symdeko/Symkevi (tezacaftor in combination with ivacaftor), Orkambi (lumacaftor in combination with ivacaftor) and Kalydeco (ivacaftor), which are collectively approved to treat around 60% of the 75,000 CF patients in North America, Europe and Australia.

Trikafta, approved in people aged 12 years and older who have at least one F508del mutation, is under review in Europe and is also being evaluated in younger patients in the United States. With approval of Trikafta, Vertex can address a significantly larger CF patient population almost 90% of patients with CF in the future.

Q1 Quarter and Outlook

Despite COVID-19 related uncertainty, Vertexs sales in 2020 are being driven by rapid uptake of Trikafta and higher international revenues due to reimbursement arrangements in key ex-U.S. countries. Trikaftas early approval and launch was a significant milestone for Vertex.

On April 29, Vertex reported Q1 results and beat estimates for earnings and sales. The 2020 outlook sparked analysts to raise EPS estimates significantly with this year getting boosted 15.8% from $7.60 to $8.80, representing 65% growth.

The company recorded total revenues of $4.16 billion in 2019, up 37%. Orkambi accounted for 29.4% of the companys total product revenues, Kalydeco accounted for 24.7%, Symdeko accounted for 35.4% and Trikafta comprised 10.5% of the same.

Vertexs dependence on the CF franchise for growth is a concern, especially as competitors would only erode market share. But Vertexs non-CF pipeline is progressing rapidly with data in multiple disease arenas expected in 2020: sickle cell disease, thalassemia and pain management.

Vertex + CRISPR = Potential Knockout Punch for Blood Disorders

Vertex is co-developing a gene editing treatment, CTX001 in partnership with CRISPR Therapeutics (CRSP) in two devastating diseases sickle cell disease and thalassemia. Phase I/II studies of CTX001 in adult transfusion-dependent b-thalassemia in Europe and sickle cell disease in the United States are ongoing.

In June 2019, Vertex announced expansion of its collaboration with CRISPR Therapeutics and acquisition of privately held Exonics Therapeutics to boost its gene editing capabilities to develop novel therapies for Duchenne muscular dystrophy (DMD) and Myotonic dystrophy type 1 (DM1).

In the April 29 update, Vertex and partner CRISPR Therapeutics said they remain on track to provide additional data from the two ongoing Phase 1/2 studies of the investigational CRISPR/Cas9 gene-editing therapy CTX001 in patients with transfusion-dependent beta thalassemia and in patients with severe sickle cell disease in 2020.

Bottom line for VRTX: The COVID-19 crisis has put the Biotech sector in the spotlight and dozens of companies are responding with resourceful R&D and robust adaptations to clinical trial interruptions. Vertex is a strong leader here and should be part of any growth-oriented healthcare-focused portfolio.

Today's Best Stocks from Zacks

Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2019, while the S&P 500 gained and impressive +53.6%, five of our strategies returned +65.8%, +97.1%, +118.0%, +175.7% and even +186.7%.

This outperformance has not just been a recent phenomenon. From 2000 2019, while the S&P averaged +6.0% per year, our top strategies averaged up to +54.7% per year.

See their latest picks free >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free reportVertex Pharmaceuticals Incorporated (VRTX) : Free Stock Analysis ReportCRISPR Therapeutics AG (CRSP) : Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment Research

View original post here:
Bull of the Day: Vertex Pharma (VRTX) - Yahoo Finance

It's not clear from the contracting notice if the land-based design would actually be the only replacement for the T-45, as NAVAIR itself has made clear that it will only be able to meet "certain requirements" for the UJTS program. The War Zone has already reached out for additional information and clarification.

It's certainly true that the T-45s, of which the Navy and the Marine Corps have around 194 in service in total, the oldest of which are now more than three decades old, are increasingly in need of a replacement. The Navy had originally planned to phase them all out in 2018, but, five years before, made to decision to instead extend their service life through 2042. The Goshawks fleet's readiness rates have slipped in recent years, raising concerns about the service's ability to train an adequate number of pilots each year. In 2019, the Government Accountability Office also warned about potential shortfalls in available aircraft as jets went through the planned Service Life Extension Program.

The T-45 fleet also suffered a worrying and deadly spate of hypoxia incidents between 2016 and 2017. Various fixes to the aircraft themselves, as well as the Navy's operating procedures, have reduced the number of subsequent physiological events in the past three years, but identifying the underlying root causes has proven difficult.

Buying an existing land-based design made to Navy specifications, but without having to modify it to withstand the stresses of catapult launches and arrested landings, could offer a low-cost, low-risk path for the Navy to acquire new jet trainers. One obvious option would be to acquire a version of the U.S. Air Force's new T-7A Red Hawk, the production of which started in January. The War Zone has already detailed the many possible future roles for the T-7A, or derivatives thereof, in the past.

There are also a number of other proven and in-production land-based jet trainer designs available, including the losing entrants for the Air Force's T-X competition, which the T-7A won. The Air Force itself recently exploring buying a small number of South Korean-made KAI T-50 Golden Eagles to support its own transformational fighter jet pilot training plans. That service canceled its proposed sole-source purchase of the T-50s in March and now says it will hold an open competition.

At the same time, whatever cost-savings the Navy might find by pursuing this course of action might be offset, at least in part, by changes that would then be necessary to its fighter pilot training pipeline. Those aviators will still need to conduct carrier qualifications and will need suitable aircraft in which to perform them. Even simply using existing F/A-18E/F Super Hornets to meet these requirements would increase the number of flight hours those jets have to dedicate to training missions, potentially pulling them away from other activities. These full-up fighters are also costly to operate.

It is worth noting that the Navy is making substantial investments in developing and fielding various technologies to help automate carrier landings. It is possible that this could eventually reduce the amount of required carrier qualification training the service feels is required, but it wouldn't eliminate it entirely. At the same time, carrier qualifications have been getting steadily pushed farther and farther down the pipeline.

The Navy has already done something broadly similar with regards to its C-2 Greyhound andE-2 Hawkeye aircraft. Prospective pilots destined to fly those aircraft conduct much of their training in the T-44, a variant of the Beechcraft King Air, which is also not carrier-capable. It's not clear how that training pipeline may also now change as the C-2s get replaced by the CMV-22B Osprey tilt-rotor. Still, as long as manned fighter jets operate from its carriers, there will be a need to have those pilots practice the uniquely complicated process of landing on, as well as taking off from, those flattops.

Regardless, the Navy's plans to buy non-carrier-capable jet trainers to replace its T-45s, even in part, points to major changes coming in how the service prepares prospective fighter pilots for the challenges involved in joining its carrier air wings.

Contact the author: joe@thedrive.com

Read more:
The Navy's Next Jet Trainer Won't Be Able To Land Or Take Off From An Aircraft Carrier - The Drive

The Department of Defense has begun to ratchet up spending to recapitalize the U.S. strategic nuclear triad and its supporting infrastructure, as several programs move from research and development into the procurement phase. The projected Pentagon expenditures are at least $167 billion from 2021-2025. This amount does not include the large nuclear warhead sustainment and modernization costs funded by the Department of Energy, projected to cost $81 billion over the next five years.

Nuclear forces require modernization, but that will entail opportunity costs.In a budget environment that offers little prospect of greater defense spending, especially in the COVID19 era, more money for nuclear forces will mean less funding for conventional capabilities.

That has potentially negative consequences for the security of the United States and its allies. While nuclear forces provide day-to-day deterrence, the Pentagon leadership spends most of its time thinking about how to employ conventional forces to manage security challenges around the world. The renewed focus on great power competition further elevates the importance of conventional forces. It is important to get the balance between nuclear and conventional forces right, particularly as the most likely path to use of nuclear arms would be an escalation of a conventional conflict. Having robust conventional forces to prevail in or deter a conventional conflict in the first place could avert a nuclear crisis or worse.

For the foreseeable future, the United States will continue to rely on nuclear deterrence for its security and that of its allies (whether we should be comfortable with that prospect is another question).Many U.S. nuclear weapons systems are aging, and replacing them will cost money, lots of money.The Pentagons five-year plan for its nuclear weapons programs proposes $29 billion in fiscal year 2021, rising to $38 billion in fiscal year 2025, as programs move from research and development to procurement.The plan envisages a total of $167 billion over five years.And that total may be understated; weapons costs increase not just as they move to the procurement phase, but as cost overruns and other issues drive the costs up compared to earlier projections.

The Pentagon knew that the procurement bow wave of nuclear weapons spending would hit in the 2020s and that funding it would pose a challenge.In October 2015, the principal deputy undersecretary of defense said Were looking at that big bow wave and wondering how the heck were going to pay for it and probably thanking our stars that we wont be here to have to answer the question.

The Pentagons funding request for fiscal year 2021 includes $4.4 billion for the new Columbia-class ballistic missile submarine that will replace Ohio-class submarines, which will begin to be retired at the end of the decade; $1.2 billion for the life extension program for the Trident II submarine-launched ballistic missile (SLBM); $1.5 billion for the Ground Based Strategic Deterrent, an intercontinental ballistic missile (ICBM) to replace the Minuteman III ICBM; $2.8 billion for the B-21 stealth bomber that will replace the B-1 and B-2 bombers; $500 million for the Long-Range Standoff Missile that will arm B-52 and B-21 bombers; and $7 billion for nuclear command, control and communications systems.

The Pentagon funds primarily go to delivery and command and control systems for nuclear weapons.The National Nuclear Security Administration at the Department of Energy bears the costs of the warheads themselves. It seeks $15.6 billion for five nuclear warhead life-extension and other infrastructure programs in fiscal year 2021, the first year of a five-year plan totaling $81 billion.The fiscal year 2021 request is nearly $3 billion more than the agency had earlier planned to ask, which suggests these programs are encountering significant cost growth.

Some look at these figures and the overall defense budget (the Pentagon wants a total of $740 billion for fiscal year 2021) and calculate that the cost of building and operating U.S. nuclear forces will amount to only 6-7 percent of the defense budget.That may be true, but how relevant is that figure?

By one estimate, the cost of building and operating the F-35 fighter program for the U.S. Air Force, U.S. Navy and U.S. Marines over the programs lifetime will be $1 trillion.Amortized over 50 years, that amounts to $20 billion per year or only 2.7 percent of the Defense Departments fiscal year 2021 budget request.The problem is that these percentages and lots of other small percentages add up.When one includes all of the programs, plus personnel and readiness costs as well as everything else that the Pentagon wants, the percentages will total to more than 100 percent of the figure that Congress is prepared to appropriate for defense.

The defense budget is unlikely to grow.Opportunity costs represent the things the Pentagon has to give up or forgo in order to fund its nuclear weapons programs.The military services gave an indication of these costs with their unfunded priorities lists, which this year total $18 billion.These show what the services would like to buy if they had additional funds, and that includes a lot of conventional weapons.

The Air Force, for example, would like to procure an additional twelve F-35 fighters as well as fund advance procurement for an additional twelve F-35s in fiscal year 2022. It would also like to buy three more tanker aircraft than budgeted.

The Army is reorienting from counter-insurgency operations in places such as Afghanistan and Iraq to facing off against major peer competitors, that is, Russia and China.Its wish list includes more long-range precision fires (artillery and short-range surface-to-surface missiles), a new combat vehicle, helicopters and more air and missile defense systems.

The Navy would like to add five F-35s to its aircraft buy, but its bigger desire is more attack submarines and warships, given its target of building up to a fleet of 355 ships. The Navy termed a second Virginia-class attack submarine its top unfunded priority in fiscal year 2021.It has set a requirement for 66 attack submarines and currently has about 50.However, as older Los Angeles-class submarines retire, that number could fall to 42. Forgoing construction of a Virginia-class submarine does not help to close that gap.

Moreover, the total number of Navy ships, now 293, will decline in the near term, widening the gap to get to 355.The Navys five-year shipbuilding program cut five of twelve planned Arleigh Burke-class destroyers, and cost considerations have led the Navy to decide to retire ten older Burke-class destroyers rather than extend their service life for an additional ten years.This comes when China is rapidly expanding its navy, and Russian attack submarines are returning on a more regular cycle to the Atlantic Ocean.

The Navy has said that funding the first Columbia-class ballistic missile submarine forced a cut-back in the number of other ships in its fiscal 2021 shipbuilding request.The decision not to fund a second Virginia-class attack submarine appears to stem directly from the unexpected $3 billion plus-up in funding for the National Nuclear Security Administrations fiscal year 2021 programs.

These are the opportunity costs of more nuclear weapons:fewer dollars for aircraft, ships, attack submarines and ground combat equipment for conventional deterrence and defense.

The principal driving factor behind the size of U.S. nuclear forces comes from Russian nuclear forces and doctrine.Diverse and effective U.S. nuclear forces that can deter a Russian nuclear attack should suffice to deter a nuclear attack by any third country.In contrast to the Cold War, the U.S. military no longer seems to worry much about a bolt from the bluea sudden Soviet or Russian first strike involving a massive number of nuclear weapons designed to destroy the bulk of U.S. strategic forces before they could launch.That is because, under any conceivable scenario, sufficient U.S. strategic forcesprincipally on ballistic missile submarines at seawould survive to inflict a devastating retaliatory response.

The most likely scenario for nuclear use between the United States and Russia is a regional conflict fought at the conventional level in which one side begins to lose and decides to escalate by employing a small number of low-yield nuclear weapons, seeking to reverse battlefield losses and signal the strength of its resolve.Questions thus have arisen about whether Russia has an escalate-to-deescalate doctrine and whether the 2018 U.S. nuclear posture review lowers the threshold for use of nuclear weapons.

If the United States and its allies have sufficiently robust conventional forces, they can prevail in a regional conflict at the conventional level and push any decision about first use of nuclear weapons onto the other side (Russia, or perhaps China or North Korea depending on the scenario).The other side would have to weigh carefully the likelihood that its first use of nuclear weapons would trigger a nuclear response, opening the decidedly grim prospect of further nuclear escalation and of things spinning out of control.The other sides leader might calculate that he/she could control the escalation, but that gamble would come with no guarantee. It would appear a poor bet given the enormous consequences if things go wrong.Happily, the test has never been run.

This is why the opportunity costs of nuclear weapons programs matter. If those programs strip too much funding from conventional forces, they weaken the ability of the United States and its allies to prevail in a conventional conflictor to deter that conflict in the first placeand increase the possibility that the United States might have to employ nuclear weapons to avert defeat.

For the United States and NATO members, that could mean reemphasis on an aspect of NATOs Cold War defense policy. In the 1960s, 1970s and early 1980s, NATO allies faced Soviet and Warsaw Pact conventional forces that had large numerical advantages, and NATO leaders had doubts about their ability to defeat a Soviet/Warsaw Pact attack at the conventional level.NATO policy thus explicitly envisaged that, if direct defense with conventional means failed, the Alliance could deliberately escalate to nuclear weapons.That left many senior NATO political and military officials uneasy.Among other things, it raised uncomfortable questions about the willingness of an American president to risk Chicago for Bonn.

Russia found itself in a similar situation at the end of the 1990s.With a collapsing economy following the break-up of the Soviet Union, the Russian government had to cut defense spending dramatically.As its conventional capabilities atrophied, Moscow adopted a doctrine envisaging first use of nuclear weapons to compensate.(In the past fifteen years, as Russias defense spending has increased, a significant amount has gone to modernizing conventional forces.)

The United States and NATO still retain the option of first use of nuclear weapons.If the U.S. president and NATO leaders were to consider resorting to that option, they then would be the ones to have to consider the dicey bet that the other side would not respond with nuclear arms or that, if it did, nuclear escalation somehow could be controlled.

Assuring NATO allies that the United States was prepared to risk Chicago for Bonn consumed a huge amount of time and fair amount of resources during the Cold War.At one point, the U.S. military deployed more than 7000 nuclear weapons in Europe to back up that assurance.Had NATO had sufficiently strong conventional forces, the Alliance would have been able to push that risky decision regarding nuclear first use onto Moscowor even have been able to take comfort that the allies conventional power would suffice to deter a Soviet/Warsaw Pact attack.

In modernizing, maintaining and operating a safe, secure and effective nuclear deterrent, the United States should avoid underfunding conventional forces in ways that increase the prospect of conventional defeat and/or that might tempt an adversary to launch a conventional attack.If Washington gets the balance wildly out of sync, it increases the possibility that the president might face the decision of whether to use nuclear weapons firstknowing that first use would open a Pandoras box of incalculable and potentially catastrophic consequences.

This means that the Department of Defense and Congress should take a hard look at the balance.The Pentagon presumably has weighed the trade-offs, though it is not a unitary actor. Nuclear weapons are our top priority has been the view of the leadership.The trade-offs have been easier to manage in the past several years, when nuclear programs were in the research and development phase, and defense budgets in the first three years of the Trump administration grew.As nuclear programs move into the more expensive procurement phase and the fiscal year 2021 budget shows little increase, the challenge of getting the balance right between nuclear and conventional spending has become more acute.It is not apparent that the Pentagon has weighed the opportunity costs over the next ten-fifteen years under less optimistic budget scenarios.

As for Congress, which ultimately sets and approves the budget, no evidence suggests that the legislative branch has closely considered the nuclear vs. conventional trade-offs.

All that was before COVID19.The response to the virus and dealing with the economic disruption it has caused have generated a multi-trillion-dollar budget deficit in 2020 and likely will push up deficits in at least 2021.It would be wise now to consider the impact of COVID19.

Having added trillions of dollars to the federal deficit, and facing an array of pressing health and social needs, will Congress be prepared to continue to devote some 50 percent of discretionary funding to the Department of Defenses requirements?Quite possibly not.If defense budgets get cut, the Pentagon will face a choice: shift funds from nuclear to conventional force programs, or accept shrinkage of U.S. conventional force capabilities andas the United States did in the 1950s and early 1960srely on nuclear deterrence to address a broader range of contingencies. In the latter case, that would mean accepting, at least implicitly, a greater prospect that the president would have to face the question of first use of nuclear weapons, i.e., a conventional conflict in which the United States was losing.

This is not to suggest that the U.S. military should forgo the strategic triad.Trident II SLBMs onboard ballistic missile submarines at sea remain the most survivable leg of the strategic deterrent.The bomber/air-breathing leg offers flexibility and can carry out conventional missions.The ICBM leg provides a hedge against a breakthrough in anti-submarine warfare.Moreover, if in a crisis or a conventional conflict, the Russian military were to develop the capability to attack U.S. ballistic missile submarines at sea, the Kremlin leadership might well calculate that it could do so without risking a nuclear response.Attacking U.S. ICBMs, on the other hand, would necessitate pouring hundreds of nuclear warheads into the center of America.A Russian leader presumably would not be so foolish as to think there would be no nuclear retaliation.

While sustaining the ICBM leg, one can question whether maintaining 400 deployed ICBMs, as the current plan envisages, is necessary.Reducing that number for the Ground-Based Strategic Deterrent (GBSD) would achieve budget savings, albeit later in the production run. Another question is whether some way might be found to extend the service life of some portion of the current Minuteman III force that would allow delaying the GBSD program, which is projected to cost $100 billion, by ten-fifteen years and postponing those costsfreeing up funds in the near term for conventional force requirements.

Another issue concerns the Long-Range Standoff Missile (LRSO) and its cost, estimated at some $20 billion when including the nuclear warheads.The B-21 bomber will incorporate stealth and advanced electronic warfare capabilities allowing it to operate against and penetrate sophisticated air defenses.The LRSO, to be deployed beginning in 2030, is intended to replace older air-launched cruise missiles carried by the B-52 bomber and could later equip the B-21 if it loses its ability to penetrate.

An alternative plan would convert B-52s in 2030 to conventional-only missions and delay the LRSO to a future point if/when it appeared that the B-21s ability to penetrate could come into question.By 2030, the Air Force should have a significant number of B-21s (the B-21 is scheduled to make its first flight in 2021 and enter service in 2025).With at least 100 planned, the Air Force should have a sufficient number of B-21s for the 300 nuclear weapons it appears to maintain at airfields where nuclear-capable bombers are currently based.

These kinds of ideas would free up billions of dollars in the 2020s that could be reallocated to conventional weapons systems.Delaying the GBSD and LRSO and their associated warhead programs by just one year (fiscal year 2021) would make available some $3 billionenough money for a Virginia-class attack submarine. Delaying those programs for ten-fifteen years would make tens of billions of dollars available for the militarys conventional force needs.

All things being equal, it is smarter and more efficient to choose to make decisions to curtail or delay major programs rather than to continue them until the money runs out and forces program termination. As it examines the administrations proposed fiscal year 2021 defense budget, Congress should carefully consider the trade-offs and press the Pentagon to articulate how it weighed the trade-offs between nuclear and conventional forces. In the end, Congress should understand whether it is funding the force that is most likely to deter not just a nuclear attack, but to deter a conventional conflict that could entail the most likely path to nuclear war.

See original here:
How COVID-19 might affect US nuclear weapons and planning - Brookings Institution

Good nutrition is vital for building up mental resilience in trying times. These are the mood-boosting vitamins and minerals to have in your mental first aid kit, says nutritionist Rob Hobson

Our minds have a lot to deal with; be it overscheduled lives, the need to succeed running us into the ground both, or the rise of burnout in the workplace. That's even before we get into the uncertainty of the current Covid-19 health crisis. According to research by the Health Survey for England approximately one in four of us in the UK will experience a mental health problem in any given year and experts are predicting numbers will rise in response to lockdown and the effects of Covid-19 on the workforce and the economy.

In Mental Health Awareness Week this week, Archbishop Justin Welby, who has talked openly about his own mental health issues, summed up the national mood when he told the BBC that there was "an overwhelming sense the world is getting more and more difficult and gloomy".

There's a lot we can do to look after our mental health and nutrition is one of the frontline ways we can support ourselves, to help build-up not just physical immunity but what psychologist Dr Meg Arrol calls 'psychological immunity'.

A strong mind is just the same as a strong immune system in that it means being able to cope well with lifes demands and with the current landscape shifting so greatly and quickly its beneficial to build up what I call psychological immunity," says Dr Arroll, a chartered psychologist working with supplement brand Healthspan.

"There are many strategies we can use to help build psychological immunity," she says, "including only checking reputable sourcing of information and talking about our feelings and taking good care of our physical health. Taking supplements that have been shown to support the mind is also a good way to help boost psychological immunity as chronic stress and traumatic experiences can deplete important vitamins and minerals."

The links between diet and mood are well documented and there are many key nutrients that play a role in maintaining energy levels and reducing the risk of depression, but it's not always easy to eat well. Low mood and poor mental health can take their toll on the food choices you make, and this can leave gaps in the diet. This is where the sensible use of supplements can be really helpful

B vitamins support the nervous system and are a key 'strong mind' ally. They can help you feel less tired, help memory and altogether make you feel like you have more clarity. They are essential for energy production in cells, including brain cells, where they help make neurotransmitters (the brains communication chemicals). They also help with nerve conduction - meaning that they help make sure messages are passed on.

When you're stressed and anxious, your B vitamins can become rapidly depleted, which can even make your stress symptoms worse. Lack of B vitamins can lead to anxiety and irritability. All the more reason to keep your levels healthy.

What the research says: Women with low levels of vitamin B1 (thiamin) are less likely to feel composed and confident and more likely to be depressed than those with higher levels, according to researchers. When they increased their intake of vitamin B1, however, they reported a marked improvement in mood and self-confidence as their thiamin levels increased. Other studies show that correcting low levels of vitamin B2 (riboflavin), vitamin B6 (pyridoxine) and vitamin B12 has beneficial effects on well-being, self-confidence and mood.

Try: Healthspan High Strength Vitamin B Complex, 8.95 for 120 tablets, Solgar Megasorb B Complex high potency, 13.99 for 50

A good nights sleep goes a long way to promoting good mental health and mood during the day. Magnesium is involved in the production of melatonin, the hormone that controls our sleep cycle. It's a mineral that's essential for energy metabolism, reducing tiredness and fatigue and is also vital for the normal functioning of the nervous system and psychological health.

Like B vitamins, magnesium is more rapidly depleted during times of stress and anxiety creating a vicious cycle - low levels of magnesium also exacerbate these feelings. During times of stress and anxiety, a magnesium supplement may be useful to balance mood and mental wellbeing.

If you suffer from PMS, magnesium is your friend. Magnesium levels appear to be significantly lower. Taking magnesium supplements every day for two months significantly improved symptoms associated with pain and bloating, one study found. Other research has shown how supplementing with magnesium may also help to relieve premenstrual mood changes.

MORE GLOSS: Why you need magnesium in midlife more than ever

Try: Healthspan Opti-Magnesium, 10.95 for 90 tablets or Magnesium Flakes Bath Soak, 9.95, 1kg pouch. NeuroMag for brain health by Life Extension 32 for 50.

You probably know that probiotics are live bacteria that have beneficial effects on digestive health and general immunity. More recent research suggests they may also influence our psychological health, the gut-brain axis.

Although research is in its early stages, probiotic bacteria are now believed to have indirect effects on our brain by regulating the production of serotonin within the gut wall. Serotonin helps to lift mood and improve anxiety and depression. As much as 95 per cent of our serotonin is made within the lining of our digestive tract.

Try: Symprove Liquid probiotic, from 21.95

MORE GLOSS: Which probiotics to eat, drink and buy - and why

5-Hydroxytryptophan, or 5-HTP, is an amino acid that is found naturally in the body and which can be converted into serotonin that regulates mood as well as melatonin, which helps to regulate the sleep cycle.

5-HTP appears to improve the structure of your sleep by extending the amount of time you spend in REM sleep in which your brain processes memories. Getting sufficient REM sleep is essential for feeling rejuvenated during the day which will inevitably impact on your mental state and ability to perform your daily tasks.

Several studies show that 5-HTP supplements have a positive effect on low mood and are better than placebo in treating depression, with benefits usually occurring within two weeks

One study, involving 60 people with a first episode of depression, showed that is was almost as good as prescription antidepressants. It compared the effects of 5-HTP with the prescribed antidepressant drug, fluoxetine, for eight weeks. Both groups showed a significant and nearly equal improvement in depression, starting from the second week of treatment and increasing over the eight weeks. By the end of the study, 73 per cent of those taking 5-HTP and 80 per cent taking fluoxetine felt significantly better.

Try: 5-HTP, 13.95 for 60 tablets or Serotone 5-HTP by Higher Nature 32.70 for 90 capsules

I've tackled these together because omega-3 fish oils and vitamin D work hand in hand to optimise serotonin (good mood hormone) levels in the brain. You don't need to know the science but if you're interested...

Serotonin needs an amino acid, called tryptophan (see 5HTP above) to convert it to a usable form in the brain. That conversion is activated by vitamin D.

Once serotonin is made, EPA (one of the long-chain omega-3 fatty acids found in fish oils) helps brain cells release it into their communication gaps (synapses) to stimulate surrounding brain cells. Once serotonin arrives at a new brain cell, the presence of another long-chain omega-3 fish oil, DHA, helps the serotonin message to be received by increasing the fluidity of the cell membrane fluidity. Good levels of vitamin D and both omega-3s are therefore needed for optimum brain function.

Researchers have suggested that lack of vitamin D, EPA or DHA contributes to a number of psychiatric disorders and depression. Clinical trials suggest that omega-3 fish oils can improve depression, prolong periods of remission from depressive episodes and improve the short-term course of the illness in those affected.

How much omega 3 do you need to take to get a beneficial anti-depressive effect? Look for 650mg total DHA and EPA per day. Adding fish oils (2g per day) to usual drug treatment for depression has also been shown to significantly improve symptoms within two weeks, compared with placebo.

Try: Healthspan High Strength Omega 3, 11.95 for 360 capsules, Bare Biology Lion Heart Pure Omega 3, 28.50 and Healthspan Super Strength Vitamin D3, 8.95 for 120 capsules, D-Lux 3000 Vitamin D Spray 7.99

MORE GLOSS: The best vitamin D supplements to support your immune system right now

NB: Supplements do have a role to play in maintaining overall health and especially people who do not manage to eat a well-balanced diet. Exploring the use of supplements to complement your mood and overall health regime may be a good option but do check if you are on any SSRIs (Selective Serotonin Reuptake Inhibitor, SSRI are antidepressants) or medication and look for supplements that are made to GMP (good manufacturing practice) such as those made by Healthspan which means they are made to high pharmaceutical standards so simply put, what it says is on the packet is actually in the product you are taking. Rob Hobson is a Registered Nutritionist and Head of Nutrition for Healthspan.

More:
The best supplements to look after your mind and mental health - Get The Gloss

The Global Packaging Coatings Market Analysis to 2027 is a specialized and in-depth study of the chemicals and materials industry with a special focus on the global market trend analysis. The report aims to provide an overview of packaging coatings market with detailed market segmentation by type, substrate, application, end user and geography. The global packaging coatings market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading packaging coatings market players and offers key trends and opportunities in the market.

Download PDF Sample Copy Here https://www.theinsightpartners.com/sample/TIPRE00004238/

The Covid-19 (coronavirus) pandemic is impacting society and the overall economy across the world. The impact of this pandemic is growing day by day as well as affecting the supply chain. The COVID-19 crisis is creating uncertainty in the stock market, massive slowing of supply chain, falling business confidence, and increasing panic among the customer segments. The overall effect of the pandemic is impacting the production process of several industries including Chemicals and Materials, and many more. Trade barriers are further restraining the demand- supply outlook. As government of different regions have already announced total lockdown and temporarily shutdown of industries, the overall production process being adversely affected; thus, hinder the overall Packaging Coatings market globally. This report on Packaging Coatings market provides the analysis on impact on Covid-19 on various business segments and country markets. The report also showcase market trends and forecast to 2027, factoring the impact of Covid -19 Situation.

Major vendors covered in this report:

Get Discount on This Report at https://www.theinsightpartners.com/discount/TIPRE00004238/

Packaging coatings are coatings having good adhesion to metal and plastic substrates along with high chemical resistance. Such coatings effectively serve protection, performance as well as decoration purposes for metal cans, plastic tubes, or any other substrate used in packaging. Coating technology in the food packaging sector allows more rational use of the materials used within this sector. Replacement of multi-layer, heavy structures with multi-functional thin layer will not only help to reduce the upstream amount of packaging material but also improve the functionality of the final packaging, thereby, ensuring shelf life extension. The packaging coatings market is coming up with highly sophisticated and engineered coatings to meet consumer convenience.

The packaging coatings market is anticipated to grow in the forecast period owing to driving factors such as rapid growth of the e-commerce industry and high demands of flexible packaging for consumer goods. Moreover, the growing demands for canned food and beverages coupled with aerosol cans for personal and healthcare industry further fuel the packaging coatings market growth. However, rising concerns on amount of Bisphenol-A in packaging coatings may limit market growth. The growth opportunity for key players in the packaging coatings market lies in the production of environment-friendly packaging coatings.

Purchase this Report at https://www.theinsightpartners.com/buy/TIPRE00004238/

The study conducts SWOT analysis to evaluate strengths and weaknesses of the key players in the Packaging Coatings market. Further, the report conducts an intricate examination of drivers and restraints operating in the market. The report also evaluates the trends observed in the parent market, along with the macro-economic indicators, prevailing factors, and market appeal according to different segments. The report also predicts the influence of different industry aspects on the Packaging Coatings market segments and regions.

The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides an overview and forecast of the global packaging coatings market based on various segments. It also provides market size and forecast estimates from the year 2017 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The packaging coatings market by each region is later sub-segmented by respective countries and segments. The report covers the analysis and forecast of 18 countries globally along with the current trend and opportunities prevailing in the region.

Our reports will help clients solve the following issues:

Insecurity about the future:

Our research and insights help our clients anticipate upcoming revenue compartments and growth ranges. This will help our clients invest or divest their assets.

Understanding market opinions:

It is extremely vital to have an impartial understanding of market opinions for a strategy. Our insights provide a keen view on the market sentiment. We keep this reconnaissance by engaging with Key Opinion Leaders of a value chain of each industry we track.

Understanding the most reliable investment centers:

Our research ranks investment centers of market by considering their future demands, returns, and profit margins. Our clients can focus on most prominent investment centers by procuring our market research.

Evaluating potential business partners:

Our research and insights help our clients identify compatible business partners.

Contact Us:

Call: +1-646-491-9876

Email:[emailprotected]

See the original post here:
Packaging Coatings Market by Top Key Players, Applications and Forecast Report 2020-2027 - Cole of Duty

Four of six patients in case series were weaned off respiratory support

An investigational allogeneic cell therapy using cardiosphere-derived cells (CDC) showed an acceptable safety profile with early evidence of efficacy in the treatment of very severe Covid-19 in a case series involving six patients treated at Cedars-Sinai Medical Center in Los Angeles.

All six patients treated with the intravenous allogeneic CDC formulation CAP-1002 (Capricor Therapeutics) as a compassionate therapy required respiratory support prior to treatment, with five on mechanical ventilation.

No adverse events related to the treatment were reported, and four of the six patients were successfully weaned from respiratory support and were discharged from the hospital as of late April.

The other two patients are still alive, but remain intubated, Cedars-Sinai cardiologist Raj Makkar, MD, confirmed to BreakingMED Wednesday, May 13.

While we are encouraged by these findings, it is important to point out that the only way that we can assess the efficacy of this treatment in a definitive way is with a randomized clinical trial, and that is what we intend to do, Makkar said.

He added that the clinical trial, which is in the planning stages, is likely to include Covid-19 patients who are not as critically ill as the six in the case series.

All of these patients required respiratory support and they were all on a downward trajectory when treated, he said. They were getting worse and we had nothing else to offer them.

Cardiosphere-derived cells are stromal/progenitor cells from heart tissue with a distinctive antigenic profile (CD105+, CD45-, CD90low).

In their case series, published in the journal Basic Research in Cardiology, Makkar and colleagues noted that the cells are entirely distinct from the controversial c-kit+ putative cardiac progenitors, which have been the subject of various retracted studies.

Since CDCs were first isolated in 2007, the cells have been tested in more than 200 patients in clinical trials for a variety of conditions with a good safety profile, including in young boys with Duchenne muscular dystrophy.

Makkar said the anti-inflammatory and antifibrotic properties of CDCs in animal models make them a possible target therapy for Covid-19.

The prior testing gave us reasonable confidence that this treatment was safe, he said, adding that there is also evidence of a favorable effect on the same type of proinflammatory cytokines that are up-regulated in Covid-19.

Comparisons to mesenchymal stem cells (MSCs) in pre-clinical models suggest that CDCs may also be more effective for paracrine factor secretion and myocardial remodeling.

Given the safety record of CDCs in humans, and the substantial body of evidence confirming relevant disease-modifying bioactivity, applicability to Covid-19 seemed compelling, particularly in the hyperinflammatory stage of the illness, the researchers wrote.

All six patients treated with the intravenous CDC formulation had severe, confirmed Covid-19 with respiratory failure and they were not receiving any other experimental agent, with the exception of hydroxychloroquine and tocilizumab.

Lack of clinical improvement or deterioration despite standard care was the primary reason for considering patients for treatment with CAP-1002. Exclusion criteria included known hypersensitivity to DMSO, which is a component of CAP-1002; prior stem cell therapy; pre-existing terminal illness; and need for mechanical circulatory support and dialysis.

In general, patients with multi-organ failure who were deemed to be too sick for any intervention were excluded from the study, Makkar and colleagues wrote.

All patients had acute respiratory distress syndrome (ARDS) prior to infusion, with decreased PaO2/FiO2 ratios (range 69-198; median 142), diffuse bilateral pulmonary infiltrates on chest imaging and evidence of preserved cardiac function on transthoracic echocardiography (LVEF range, 50-75%). SOFA scores ranged from 2 to 8 prior to stem cell treatment.

The six patients (age range, 19-75 years) had IV infusions of CAP-1002 containing 150 million allogeneic CDCs, and two of the six had a second dose of the treatment.

Following treatment, four patients (67%) were weaned from respiratory support and discharged from the hospital.

A contemporaneous control group of critically ill Covid-19 patients (n = 34) at our institution showed 18% overall mortality at a similar stage of hospitalization, the researchers wrote.

Ferritin was elevated in all patients at baseline (range of all patients 605.43-2991.52 ng/ml) and decreased in five of the six patients (range of all patients 252.891029.90 ng/ml).

Absolute lymphocyte counts were low in five of the six patients at baseline (range 0.260.82 103/l) but had increased in 3 of these five at last follow-up (range 0.231.02 103/l).

Administration of CAP-1002 as a compassionate therapy for patients with severe Covid-19 and significant comorbidities was safe, well tolerated without serious adverse events, and associated with clinical improvement, as evidenced by extubation (or prevention of intubation, the researchers wrote.

Stem cell therapy utilizing cardiosphere-derived cells (CDC) showed an acceptable safety profile with early evidence of efficacy in the treatment of very severe Covid-19 in an early case series involving 6 patients treated at Cedars-Sinai Medical Center, Los Angeles.

No adverse events related to the treatment were reported, and four of the six patients were successfully weaned from respiratory support and were discharged from the hospital.

Salynn Boyles, Contributing Writer, BreakingMED

Funding for this story was provided by the Smidt Family Foundation. The cell product, CAP-1002, was provided by manufacturer Capricor Therapeutics.

ResearcherEduardo Marban reported owning founders equity in Cariricor Therapeutics, and researcher Linda Marban reported being an employee and owning equity in the company.

Cat ID: 125

Topic ID: 79,125,254,930,287,728,932,570,574,730,933,125,190,926,192,927,151,928,925,934

Read the original:
Cardio Stem Cell Therapy Used to Treat Critically Ill Covid-19 Patients - Physician's Weekly

Not intended for UK-based media

- Results from two studies of BAVENCIOto be featured in ASCO press briefing

- Primary efficacy, biomarker and HRQoL analyses for tepotinib, the first MET inhibitor to have received a regulatory approval for NSCLC with METgene alterations

- Two-year follow-up for first-in-class bifunctional immunotherapy bintrafusp alfatargeting TGF-/PD-L1, in second-line NSCLC

ROCKLAND,Massachusetts, May 13, 2020 /PRNewswire/ --EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the US and Canada,today announced data for its innovative investigational agents and investigational uses of marketed medicines to be presented at the American Society of Clinical Oncology (ASCO) ASCO20 Virtual Scientific Program, to be held virtually from May 29-31.

This year, ASCO will be highlightingduring its embargoed presscast on Tuesday, May 26 and at the plenary session on Sunday, May 31the Phase III JAVELIN Bladder 100 study (Abstract# LBA1) of BAVENCIO (avelumab) in the first-line maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma (UC)*. Additional data will be presented for early- to late-stage molecules discovered and developed in-house that demonstrate the Company's commitment and relentless drive to discover, develop and deliver innovative treatment options in its hope to turn cancer patients into cancer survivors. Research from several investigator-sponsored and collaborative research studies also will be shared. This includes a late-breaking oral presentation of results of the investigator-sponsored, multicenter Phase II TROPHIMMUN study of avelumab for the treatment of chemotherapy-resistant gestational trophoblastic tumors (Cohort A), which also will be featured in the ASCO press program (Abstract# LBA6008).

"Despite the many advances in cancer treatment, we have an urgency to continue to discover and develop innovative treatment options that will have a major impact on the lives of people living with cancer,"said Luciano Rossetti, Global Head of Research & Development for EMD Serono. "Taking on this challenge, we've applied our deep knowledge of cancer biology to highly focused areas to develop the first-in-class oral MET inhibitor, tepotinib, which received the first approval anywhere in the world for the treatment of NSCLC with MET gene alterations, and our first-in-class bifunctional fusion protein immunotherapy, bintrafusp alfa, both of which have promising outcomes featured at this year's ASCO meeting."

For tepotinib, approved in Japan for the treatment of patients withunresectable, advanced or recurrent non-small cell lung cancer (NSCLC) with METexon 14 (METex14)skipping alterationsand the first oral MET inhibitor indicated for the treatment of advanced NSCLC harboring MET gene alterations to receive a regulatory approval, data will be presented from the primary analysis of the VISION study with promising activity in patients with advanced EGFR/ALK wild-type, METex14 skipping NSCLC who were prospectively enrolled using liquid biopsy or tissue biopsy. Results (Abstract #9556) include6-month follow-updata for the primary endpoint of objective response rate (ORR) as determined by independent review committee. Secondary endpoints include ORR as assessed by investigators, duration of response, disease control rate, progression-free survival, molecular responses, and safety data. Additionally, patient-reported outcomes (PROs) of health-related quality of life (HRQoL) for the VISION study will be presented at the meeting (Abstract# 9575). These outcomes are the first time HRQoL have been reported for patients with METex14skipping NSCLC.

For bintrafusp alfa, a novel bifunctional fusion protein targeting TGF- and PD-L1, two-year follow-up data from a global Phase I study in second-line NSCLC will be presented (Abstract# 9558). These data continue to show manageable safety with durable responses and encouraging long-term survival, especially in patients with high PD-L1 expression (80%). The overall safety profile has remained consistent since the interim analysis, with no new safety signals or deaths and one additional treatment-related discontinuation (blood alkaline phosphatase increased). Studies in the bintrafusp alfa lung cancer program include:

The Company's broad portfolio of investigational DNA damage response (DDR) inhibitors represents multiple development paths, including combinations with other agents and modalities. A trial-in-progress poster (Abstract #TPS4117) will review a multicenter Phase Ib/II study evaluating the safety, tolerability, pharmacokinetics and efficacy of the DNA-PK inhibitor peposertib (formerly M3814) in combination with capecitabine and radiotherapy as neoadjuvant treatment in patients with locally advanced rectal cancer.

*BAVENCIO is under clinical investigation for the first-line maintenance treatment of advanced UC. There is no guarantee that BAVENCIO will be approved for first-line maintenance treatment of advanced UC by any health authority worldwide.

Tepotinib is currently under clinical investigation in NSCLC and not yet approved in any markets outside of Japan.

Bintrafusp alfa is currently under clinical investigation and not approved for any use anywhere in the world.

About BAVENCIO (avelumab)

BAVENCIO is a human anti-programmed death ligand-1 (PD-L1) antibody. BAVENCIO has been shown in preclinical models to engage both the adaptive and innate immune functions. By blocking the interaction of PD-L1 with PD-1 receptors, BAVENCIO has been shown to release the suppression of the T cell-mediated antitumor immune response in preclinical models.10-12 In November 2014, Merck KGaA, Darmstadt, Germany and Pfizer announced a strategic alliance to co-develop and co-commercialize BAVENCIO.

BAVENCIO Approved Indications

BAVENCIO (avelumab) in combination with axitinib is indicated in the US for the first-line treatment of patients with advanced renal cell carcinoma (RCC).

In the US, the FDA granted accelerated approval for BAVENCIO for the treatment of (i) adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma (mMCC) and (ii) patients with locally advanced or metastatic urothelial carcinoma (mUC) who have disease progression during or following platinum-containing chemotherapy, or have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. These indications are approved under accelerated approval based on tumor response rate and duration of response. Continued approval for these indications may be contingent upon verification and description of clinical benefit in confirmatory trials.

Avelumab is currently approved for patients with MCC in 50 countries globally, with the majority of these approvals in a broad indication that is not limited to a specific line of treatment.

BAVENCIO Important Safety Information from the US FDA-Approved Label

BAVENCIO can cause immune-mediated pneumonitis, including fatal cases. Monitor patients for signs and symptoms of pneumonitis, and evaluate suspected cases with radiographic imaging. Administer corticosteroids for Grade 2 or greater pneumonitis. Withhold BAVENCIO for moderate (Grade 2) and permanently discontinue for severe (Grade 3), life-threatening (Grade 4), or recurrent moderate (Grade 2) pneumonitis. Pneumonitis occurred in 1.2% of patients, including one (0.1%) patient with Grade 5, one (0.1%) with Grade 4, and five (0.3%) with Grade 3.

BAVENCIO can cause hepatotoxicity and immune-mediated hepatitis, including fatal cases. Monitor patients for abnormal liver tests prior to and periodically during treatment. Administer corticosteroids for Grade 2 or greater hepatitis. Withhold BAVENCIO for moderate (Grade 2) immune-mediated hepatitis until resolution and permanently discontinue for severe (Grade 3) or life-threatening (Grade 4) immune-mediated hepatitis. Immune-mediated hepatitis occurred with BAVENCIO as a single agent in 0.9% of patients, including two (0.1%) patients with Grade 5, and 11 (0.6%) with Grade 3.

BAVENCIO in combination with axitinib can cause hepatotoxicity with higher than expected frequencies of Grade 3 and 4 alanine aminotransferase (ALT) and aspartate aminotransferase (AST) elevation. Consider more frequent monitoring of liver enzymes as compared to when the drugs are used as monotherapy. Withhold BAVENCIO and axitinib for moderate (Grade 2) hepatotoxicity and permanently discontinue the combination for severe or life-threatening (Grade 3 or 4) hepatotoxicity. Administer corticosteroids as needed. In patients treated with BAVENCIO in combination with axitinib, Grades 3 and 4 increased ALT and AST occurred in 9% and 7% of patients, respectively, and immune-mediated hepatitis occurred in 7% of patients, including 4.9% with Grade 3 or 4.

BAVENCIO can cause immune-mediated colitis. Monitor patients for signs and symptoms of colitis. Administer corticosteroids for Grade 2 or greater colitis. Withhold BAVENCIO until resolution for moderate or severe (Grade 2 or 3) colitis until resolution. Permanently discontinue for life-threatening (Grade 4) or recurrent (Grade 3) colitis upon reinitiation of BAVENCIO. Immune-mediated colitis occurred in 1.5% of patients, including seven (0.4%) with Grade 3.

BAVENCIO can cause immune-mediated endocrinopathies, including adrenal insufficiency, thyroid disorders, and type 1 diabetes mellitus.

Monitor patients for signs and symptoms of adrenal insufficiency during and after treatment, and administer corticosteroids as appropriate. Withhold BAVENCIO for severe (Grade 3) or life-threatening (Grade 4) adrenal insufficiency. Adrenal insufficiency was reported in 0.5% of patients, including one (0.1%) with Grade 3.

Thyroid disorders can occur at any time during treatment. Monitor patients for changes in thyroid function at the start of treatment, periodically during treatment, and as indicated based on clinical evaluation. Manage hypothyroidism with hormone replacement therapy and hyperthyroidism with medical management. Withhold BAVENCIO for severe (Grade 3) or life-threatening (Grade 4) thyroid disorders. Thyroid disorders, including hypothyroidism, hyperthyroidism, and thyroiditis, were reported in 6% of patients, including three (0.2%) with Grade 3.

Type 1 diabetes mellitus including diabetic ketoacidosis: Monitor patients for hyperglycemia or other signs and symptoms of diabetes. Withhold BAVENCIO and administer antihyperglycemics or insulin in patients with severe or life-threatening (Grade 3) hyperglycemia, and resume treatment when metabolic control is achieved. Type 1 diabetes mellitus without an alternative etiology occurred in 0.1% of patients, including two cases of Grade 3 hyperglycemia.

BAVENCIO can cause immune-mediated nephritis and renal dysfunction. Monitor patients for elevated serum creatinine prior to and periodically during treatment. Administer corticosteroids for Grade 2 or greater nephritis. Withhold BAVENCIO for moderate (Grade 2) or severe (Grade 3) nephritis until resolution to Grade 1 or lower. Permanently discontinue BAVENCIO for life-threatening (Grade 4) nephritis. Immune-mediated nephritis occurred in 0.1% of patients.

BAVENCIO can result in other severe and fatal immune-mediated adverse reactions involving any organ system during treatment or after treatment discontinuation. For suspected immune-mediated adverse reactions, evaluate to confirm or rule out an immune-mediated adverse reaction and to exclude other causes. Depending on the severity of the adverse reaction, withhold or permanently discontinue BAVENCIO, administer high-dose corticosteroids, and initiate hormone replacement therapy, if appropriate. Resume BAVENCIO when the immune-mediated adverse reaction remains at Grade 1 or lower following a corticosteroid taper. Permanently discontinue BAVENCIO for any severe (Grade 3) immune-mediated adverse reaction that recurs and for any life-threatening (Grade 4) immune-mediated adverse reaction. The following clinically significant immune-mediated adverse reactions occurred in less than 1% of 1738 patients treated with BAVENCIO as a single agent or in 489 patients who received BAVENCIO in combination with axitinib: myocarditis including fatal cases, pancreatitis including fatal cases, myositis, psoriasis, arthritis, exfoliative dermatitis, erythema multiforme, pemphigoid, hypopituitarism, uveitis, Guillain-Barr syndrome, and systemic inflammatory response.

BAVENCIO can cause severe or life-threatening infusion-related reactions. Premedicate patients with an antihistamine and acetaminophen prior to the first 4 infusions and for subsequent infusions based upon clinical judgment and presence/severity of prior infusion reactions. Monitor patients for signs and symptoms of infusion-related reactions, including pyrexia, chills, flushing, hypotension, dyspnea, wheezing, back pain, abdominal pain, and urticaria. Interrupt or slow the rate of infusion for mild (Grade 1) or moderate (Grade 2) infusion-related reactions. Permanently discontinue BAVENCIO for severe (Grade 3) or life-threatening (Grade 4) infusion-related reactions. Infusion-related reactions occurred in 25% of patients, including three (0.2%) patients with Grade 4 and nine (0.5%) with Grade 3.

BAVENCIO in combination with axitinib can cause major adverse cardiovascular events (MACE) including severe and fatal events. Consider baseline and periodic evaluations of left ventricular ejection fraction. Monitor for signs and symptoms of cardiovascular events. Optimize management of cardiovascular risk factors, such as hypertension, diabetes, or dyslipidemia. Discontinue BAVENCIO and axitinib for Grade 3-4 cardiovascular events. MACEoccurred in 7% of patients with advanced RCC treated with BAVENCIO in combination with axitinib compared to 3.4% treated with sunitinib. These events included death due to cardiac events (1.4%), Grade 3-4 myocardial infarction (2.8%), and Grade 3-4 congestive heart failure (1.8%).

BAVENCIO can cause fetal harm when administered to a pregnant woman. Advise patients of the potential risk to a fetus including the risk of fetal death. Advise females of childbearing potential to use effective contraception during treatment with BAVENCIO and for at least 1 month after the last dose of BAVENCIO. It is not known whether BAVENCIO is excreted in human milk. Advise a lactating woman not to breastfeed during treatment and for at least 1 month after the last dose of BAVENCIO due to the potential for serious adverse reactions in breastfed infants.

The most common adverse reactions (all grades, 20%) in patients with metastatic Merkel cell carcinoma (MCC) were fatigue (50%), musculoskeletal pain (32%), diarrhea (23%), nausea (22%), infusion-related reaction (22%), rash (22%), decreased appetite (20%), and peripheral edema (20%).

Selected treatment-emergent laboratory abnormalities (all grades, 20%) in patients with metastatic MCC were lymphopenia (49%), anemia (35%), increased aspartate aminotransferase (34%), thrombocytopenia (27%), and increased alanine aminotransferase (20%).

The most common adverse reactions (all grades, 20%) in patients with locally advanced or metastatic urothelial carcinoma (UC) were fatigue (41%), infusion-related reaction (30%), musculoskeletal pain (25%), nausea (24%), decreased appetite/hypophagia (21%), and urinary tract infection (21%).

Selected laboratory abnormalities (Grades 3-4, 3%) in patients with locally advanced or metastatic UC were hyponatremia (16%), increased gamma-glutamyltransferase (12%), lymphopenia (11%), hyperglycemia (9%), increased alkaline phosphatase (7%), anemia (6%), increased lipase (6%), hyperkalemia (3%), and increased aspartate aminotransferase (3%).

Fatal adverse reactions occurred in 1.8% of patients with advanced renal cell carcinoma (RCC) receiving BAVENCIO in combination with axitinib. These included sudden cardiac death (1.2%), stroke (0.2%), myocarditis (0.2%), and necrotizing pancreatitis (0.2%).

The most common adverse reactions (all grades, 20%) in patients with advanced RCC receiving BAVENCIO in combination with axitinib (vs sunitinib) were diarrhea (62% vs 48%), fatigue (53% vs 54%), hypertension (50% vs 36%), musculoskeletal pain (40% vs 33%), nausea (34% vs 39%), mucositis (34% vs 35%), palmar-plantar erythrodysesthesia (33% vs 34%), dysphonia (31% vs 3.2%), decreased appetite (26% vs 29%), hypothyroidism (25% vs 14%), rash (25% vs 16%), hepatotoxicity (24% vs 18%), cough (23% vs 19%), dyspnea (23% vs 16%), abdominal pain (22% vs 19%), and headache (21% vs 16%).

Selected laboratory abnormalities (all grades, 20%) worsening from baseline in patients with advanced RCC receiving BAVENCIO in combination with axitinib (vs sunitinib) were blood triglycerides increased (71% vs 48%), blood creatinine increased (62% vs 68%), blood cholesterol increased (57% vs 22%), alanine aminotransferase increased (ALT) (50% vs 46%), aspartate aminotransferase increased (AST) (47% vs 57%), blood sodium decreased (38% vs 37%), lipase increased (37% vs 25%), blood potassium increased (35% vs 28%), platelet count decreased (27% vs 80%), blood bilirubin increased (21% vs 23%), and hemoglobin decreased (21% vs 65%).

Please see full US Prescribing Information and Medication Guide available at http://www.BAVENCIO.com.

About tepotinib

Tepotinib is an oral MET inhibitor that is designed to inhibit the oncogenic MET receptor signaling caused by MET (gene) alterations, including both METex14 skipping alterations and MET amplifications, or MET protein overexpression. Discovered in-house at Merck KGaA, Darmstadt, Germany, it has been designed to have a highly selective mechanism of action,7 with the potential to improve outcomes in aggressive tumors that have a poor prognosis and harbor these specific alterations.Tepotinibis currently under clinical investigation in NSCLC and not yet approved in any markets outside of Japan.Merck KGaA, Darmstadt, Germany is actively assessing the potential of investigating tepotinib in combination with novel therapies and in other tumor indications. Tepotinib is approved under the brand name TEPMETKO in Japan for the treatment of unresectable, advanced or recurrent non-small cell lung cancer (NSCLC) with MET exon 14 (METex14) skipping alterations. The brand name TEPMETKO is not approved for use outside of Japan.

About bintrafusp alfa

Bintrafusp alfa (M7824), discovered in-house at Merck KGaA, Darmstadt, Germany, is a potential first-in-class investigational bifunctional fusion protein designed to simultaneously block two immunosuppressive pathways, TGF- and PD-L1, within the tumor microenvironment. This bifunctional approach is thought to control tumor growth by potentially restoring and enhancing anti-tumor responses.In preclinical studies, bintrafusp alfa has demonstrated antitumor activity both as monotherapy and in combination with chemotherapy. Based on its mechanism of action, bintrafusp alfa offers a potential targeted approach to addressing the underlying pathophysiology of difficult-to-treat cancers.

[emailprotected] is the global clinical trial program investigating the potential co-localized, dual inhibition of TGF- and PD-L1 with bintrafusp alfa (M7824) in multiple tumor types. Current clinical trial information can be found on the [emailprotected] website at http://www.intrapidclinicaltrials.com. To date, more than 850 patients with various types of solid tumors have been treated globally in the bintrafusp alfa [emailprotected] clinical development program.

All Merck KGaA, Darmstadt, Germany, press releases are distributed by e-mail at the same time they become available on the EMD Group Website. In case you are a resident of the USA or Canada please go to http://www.emdgroup.com/subscribeto register for your online subscription of this service as our geo-targeting requires new links in the email. You may later change your selection or discontinue this service.

About EMD Serono, Inc.

EMD Serono - the biopharmaceutical business of Merck KGaA, Darmstadt,Germany in the U.S. andCanada- is engaged in the discovery, research and development of medicines for patients with difficult to treat diseases. The business is committed to transforming lives by developing and delivering meaningful solutions that help address the therapeutic and support needs of individual patients. Building on a proven legacy and deep expertise in neurology, fertility and endocrinology, EMD Serono is developing potential new oncology and immuno-oncology medicines while continuing to explore potential therapeutic options for diseases such as psoriasis, lupus and MS. Today, the business has approximately 1,500 employees around the country with commercial, clinical and research operations based in the company's home state ofMassachusetts.www.emdserono.com.

About Merck KGaA, Darmstadt, Germany

Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across healthcare, life science and performance materials. Around 57,000 employees work to make a positive difference to millions of people's lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices the company is everywhere. In 2019, Merck KGaA, Darmstadt, Germany generated sales of 16.2 billion in 66 countries.

The company holds the global rights to the name and trademark "Merck" internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Performance Materials. Since its founding in 1668, scientific exploration and responsible entrepreneurship have been key to the company's technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company.

Contacts:

Media: Julissa Viana 781 206 5795

Investor Relations +49 6151 72-3321

SOURCE EMD Serono

See the rest here:
Breakthrough Innovation in Cancer Care From EMD Serono Pipeline to Be Presented at ASCO 2020 - PRNewswire

DUBLIN, May 18, 2020 /PRNewswire/ -- The "Global Stem Cell Partnering Terms and Agreements 2010-2020" report has been added to ResearchAndMarkets.com's offering.

This report provides comprehensive understanding and unprecedented access to the stem cell partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter Stem Cell partnering deals. These deals tend to be multicomponent, starting with collaborative R&D, and proceed to commercialization of outcomes.

This report provides details of the latest Stem Cell agreements announced in the life sciences since 2010.

The report takes the reader through a comprehensive review Stem Cell deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Stem Cell partnering deals.

The report presents financial deal term values for Stem Cell deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.

The middle section of the report explores the leading dealmakers in the Stem Cell partnering field; both the leading deal values and most active Stem Cell dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.

One of the key highlights of the report is that over 600 online deal records of actual Stem Cell deals, as disclosed by the deal parties, are included towards the end of the report in a directory format - by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.

In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

The initial chapters of this report provide an orientation of Stem Cell dealmaking.

A comprehensive series of appendices is provided organized by Stem Cell partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Stem Cell partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Stem Cell technologies and products.

Analyzing actual contract agreements allows assessment of the following:

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/9pqrta

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager [emailprotected]

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1904 Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

http://www.researchandmarkets.com

View post:
Global Stem Cell Partnering Deals Collection (2010-2020): Access to Headline, Upfront, Milestone and Royalty Data - PRNewswire

More than three months into the coronavirus pandemic, widely acknowledged shortcomings with testing continue to hamper the nations recovery. So when a team of microbiologists headed by Dr. Feng Zhang of the McGovern Institute at MIT and the Broad Institute reported this month that they had ironed out a protocol for a simple, cheap, point-of-care test that uses CRISPR to detect the virus, it was hailed as one of the most important contributions to fighting COVID-19.

Efforts to build and scale up a diagnostic have been beset by a number of snags, from a scarcity of chemicals called reagents and equipment to slow return of results. As officials debate how to safely reopen the country, those weaknesses would need to be rectified in a way where relaxing stay-at-home orders doesnt set off a viral rebound.

According to the Harvard Global Health Institute, in order to safely reopen the country and keep it open, we must ramp our testing rate from about a million per week to a million per day. But that remains a stretch by conventional means.

Enter CRISPR, the precision genome-editing technique that is anything but conventional.

Dr. Zhang and his colleagues harnessed a new type of CRISPR to build a test able to rapidly detect as few as 100 coronavirus particles in a swab or saliva sample, according to instructions for the new test, called STOPCovid, that they posted online. The teams focus has now shifted to proving that the test is safe and effective on a mass scale.

Like any diagnostic chemistry, we need to demonstrate that STOPCovid is accurate on a large enough cohort of patient samples to provide benefit, wrote Drs. Jonathan Gootenberg and Omar Abudayyeh, both of the McGovern Institute, in response to emailed questions. In addition, the current pandemic has made clear the need to scale to thousands or millions of tests, and solutions for that are necessary as well.

As to when the new diagnostic may be pressed into service against the novel coronavirus, Its hard to predict what the timeframe would be for a point-of-care or at-home test, the two noted. But given the need for these diagnostics, we would hope at latest by the end of the year.

That timeframe is possible because a prototype for a quick, easy, cheap and precise CRISPR-based diagnostic test had already existed. In 2017 Dr. Zhang and bioengineer Dr. James Collins published research showing that CRISPR could be trained to detect extremely low amounts of genetic material and was suitable for use during disease outbreaks. They dubbed this system Sherlock, for specific high-sensitivity enzymatic reporter unlocking.

Its from that earlier prototype that the new SARS-CoV-2 test takes its cue. STOP stands for Sherlock Testing in One Pot think multiple steps reduced to a single reaction in a tube. Its similar to DNA-targeting CRISPRs, like the well-known Cas9 system for DNA-editing of the human genome. Only this system has been reformulated to target strands of RNA, which are the building blocks of viruses.

Once a guide RNA molecule brings the Cas12 enzymes to the area of interest, the enzymes cut it in such a way that it generates a fluorescent readout. That readout is detectable, in much the same way home pregnancy tests pick up on pregnancy-related hormones.

Broadscale testing of the type afforded by STOPCovid would be integral to reopening the economy again, said Dr. Neville Sanjana, a genome engineer who was not involved in the CRISPR diagnostic research but whose lab, based at the New York Genome Center and NYU, is involved in several efforts using CRISPR, both COVID-related and non.

The CRISPR-based diagnostics do present a path forward not just to scaling up but to longitudinal sampling, continual sampling, said Dr. Sanjana, who, in addition to being a faculty member at the New York Genome Center, is also assistant professor of biology at New York University and of neuroscience and physiology at the NYU School of Medicine. Were only going to feel comfortable going back to work if not only do you know that your coworker was Covid-negative yesterday, but you know your coworker was Covid-negative last week and Covid-negative today if you have as many assurances as possible.

To fully appreciate why a CRISPR-based test might be a good fit in this situation requires a comparison to the standard COVID-19 test, which is based on a technology called qPCR. The qPCR tests work by detecting nucleic acids, like RNA, and amplifying them. In that sense, theyre similar to CRISPR-based tests.

However, thats where the similarities end.

The qPCR tests require a specialized piece of equipment combining a thermocycler (a machine that automatically cycles through multiple temperature changes) and a microscope. These machines are typically only found in labs and normally cost a few thousand dollars apiece. The other big limitation of qPCR is that the reagents needed to perform the test require cold storage.

CRISPR-based diagnostics, on the other hand, can assay the presence or absence of a nucleic acid at just one temperature. In addition, its been demonstrated also by Dr. Zhang and colleagues that its possible to freeze-dry CRISPR enzymes, obviating the need for cumbersome cold storage.

You dont need the microbiology lab. Instead, you maybe need a stove, said Sanjana.

One of the unique aspects of CRISPR is that it enables sensitive detection without requiring fancy equipment or refrigerated storage.

Reading the results is relatively simple, too. Whereas qPCR and PCR-based test results must be read out either using a microscope or something called agarose gel electrophoresis another lab mainstay the CRISPR-based assay for SARS-CoV-2 uses a lateral flow strip for readout, akin to a home pregnancy test.

A test strip is placed in a tube, and the presence of two lines indicates SARS-CoV-2. Results come in about an hour, the researchers say, with no special handling needed. A mobile phone app can analyze images captured by the phone camera to readout test results, they noted in their white paper.

That [kind of straightforward readout] would be an enabling technology, said Sanjana, even in places located close to a traditional lab.

Whats more, STOPCovid tested on a nasopharyngeal swab bested sensitivity and specificity rates of qPCR, according to Zhangs team (its been shown to work in saliva, too). His group has prepared reagents for 10,000 tests to make freely available to other researchers who want to evaluate its diagnostic use.

At least two other research groups are studying CRISPR technologys promise in diagnosing coronavirus. The FDA was suitably impressed with the test coming out of the Broad group, which is being commercialized through a company aptly named Sherlock, that the agency handed it an emergency use authorization this month. Meanwhile, Zhang is reportedly talking to would-be commercial partners about designing a device based on a disposable, single-use test cartridge, similar to a pregnancy test.

Thats the kind of thing we want, said Dr. Sanjana. If I had to think about what would be the ideal test, it would be something that would be dirt cheap, you could do it every single day, you could test yourself and your whole family, and youd get results instantly or close to instantly. This is what we need to go back to work safely.

Not to say that the CRISPR-based testing is the end-all-be-all, he added, but I think it can fill a very unique niche, even in places where you might have access to what you need to do qPCR-based tests. But the convenience would be greater and thus the adoption would be better.

Here is the original post:
A CRISPR-based, at-home COVID-19 test is set to arrive this year. Here's what you need to know - News - MM&M - Medical Marketing and Media

The recent outbreak of the COVID-19 (Coronavirus) pandemic has built and broken many value-grab opportunities for companies in the CRISPR and Cas Genes market. Gain full access on our latest analysis about COVID-19 and how companies in the CRISPR and Cas Genes market are capitalizing on new strategies to maintain stable revenue income. Look into our resourceful insights highlighting the impact of COVID-19 caused on the global market landscape.

Why Choose MRRSE Research?

Request Sample Report @https://www.mrrse.com/sample/17251?source=atm

The report on the global CRISPR and Cas Genes market published by Market Research Reports Search Engine(MRRSE) provides a clear understanding of the flight of the CRISPR and Cas Genes market over the forecast period (20XX-20XX). The study introspects the various factors that are tipped to influence the growth of the CRISPR and Cas Genes market in the upcoming years. The current trends, growth opportunities, restraints, and major challenges faced by market players in the CRISPR and Cas Genes market are analyzed in the report.

The study reveals that the global CRISPR and Cas Genes market is projected to reach a market value of ~US$XX by the end of 20XX and grow at a CAGR of ~XX% during the assessment period. Further, a qualitative and quantitative analysis of the CRISPR and Cas Genes market based on data collected from various credible sources in the market value chain is included in the report along with relevant tables, graphs, and figures.

Request For Discount On This Report @ https://www.mrrse.com/checkdiscount/17251?source=atm

Key Takeaways of the Report:

CRISPR and Cas Genes Market Segmentation

By Region

The presented study throws light on the current and future prospects of the CRISPR and Cas Genes market in various geographies such as:

By Product Type

The report highlights the product adoption pattern of various products in the CRISPR and Cas Genes market and provides intricate insights such as the consumption volume, supply-demand ratio, and pricing models of the following products:

Companies Mentioned in the Report

The report also profiles the major players in the market in terms of various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. Key players operating in the global CRISPR and Cas genes market include Synthego, Thermo Fisher Scientific, Inc., GenScript, Addgene, Merck KGaA (Sigma-Aldrich), Integrated DNA Technologies, Inc., Transposagen Biopharmaceuticals, Inc., OriGene Technologies, Inc., New England Biolabs, Dharmacon, Cellecta, Inc., Agilent Technologies, and Applied StemCell Inc. These players are adopting organic and in-organic growth strategies to expand product offerings, strengthen geographical reach, increase customer base, and market share.

The global CRISPR and Cas genes market has been segmented as follows:

Global CRISPR and Cas Genes Market, by Product

Global CRISPR and Cas Genes Market, by Application

Global CRISPR and Cas Genes Market, by End-user

Global CRISPR and Cas Genes Market, by Region

Buy This Report @ https://www.mrrse.com/checkout/17251?source=atm

The report addresses the following doubts related to the CRISPR and Cas Genes market:

Here is the original post:
The impact of the coronavirus on the CRISPR and Cas Genes Market 2020:Key Insights, Drivers and Restraints, Opportunities and Challenges, Sales and...

After William Blair and Piper Sandler gave Crispr Therapeutics AG (NASDAQ: CRSP) a Buy rating last month, the company received another Buy, this time from Oppenheimer. Analyst Jay Olson maintained a Buy rating on Crispr Therapeutics AG yesterday and set a price target of $80.00. The companys shares closed last Friday at $61.09.

According to TipRanks.com, Olson is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -7.8% and a 39.0% success rate. Olson covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals, ACADIA Pharmaceuticals, and Enanta Pharmaceuticals.

Currently, the analyst consensus on Crispr Therapeutics AG is a Moderate Buy with an average price target of $71.83, a 28.8% upside from current levels. In a report issued on May 6, Chardan Capital also reiterated a Buy rating on the stock.

See todays analyst top recommended stocks >>

The company has a one-year high of $74.00 and a one-year low of $32.30. Currently, Crispr Therapeutics AG has an average volume of 967.6K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

CRISPR Therapeutics AG engages in the development and commercialization of therapies derived from genome-editing technology. Its proprietary platform CRISPR/Cas9-based therapeutics allows for precise and directed changes to genomic DNA. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow in 2014 and is headquartered in Zug, Switzerland.

Read this article:
Crispr Therapeutics AG (CRSP) Received its Third Buy in a Row - Smarter Analyst

A new business intelligence report released by CMI with title Global CRISPR and CAS Gene Market Research Report 2020-2027 is designed covering micro level of analysis by manufacturers and key business segments. The Global CRISPR and CAS Gene Market survey analysis offers energetic visions to conclude and study market size, market hopes, and competitive surroundings. The research is derived through primary and secondary statistics sources and it comprises both qualitative and quantitative detailing. Some of the key players profiled in the study are Caribou Biosciences Inc., CRISPR Therapeutics, Mirus Bio LLC, Editas Medicine, Takara Bio Inc., Synthego, Thermo Fisher Scientific, Inc., GenScript, Addgene, Merck KGaA (Sigma-Aldrich), Integrated DNA Technologies, Inc., Transposagen Biopharmaceuticals, Inc., OriGene Technologies, Inc., New England Biolabs, Dharmacon, Cellecta, Inc., Agilent Technologies, and Applied StemCell, Inc.

Whats keeping Caribou Biosciences Inc., CRISPR Therapeutics, Mirus Bio LLC, Editas Medicine, Takara Bio Inc., Synthego, Thermo Fisher Scientific, Inc., GenScript, Addgene, Merck KGaA (Sigma-Aldrich), Integrated DNA Technologies, Inc., Transposagen Biopharmaceuticals, Inc., OriGene Technologies, Inc., New England Biolabs, Dharmacon, Cellecta, Inc., Agilent Technologies, and Applied StemCell, Inc. Ahead in the Market? Benchmark yourself with the strategic moves and findings recently released by CMI

Get Summery Of this Report:https://www.coherentmarketinsights.com/market-insight/crispr-and-cas-gene-market-2598

Market Overview of Global CRISPR and CAS Gene

If you are involved in the Global CRISPR and CAS Gene industry or aim to be, then this study will provide you inclusive point of view. Its vital you keep your market knowledge up to date segmented by Applications and major players. If you have a different set of players/manufacturers according to geography or needs regional or country segmented reports we can provide customization according to your requirement.

This study mainly helps understand which market segments or Region or Country they should focus in coming years to channelize their efforts and investments to maximize growth and profitability. The report presents the market competitive landscape and a consistent in depth analysis of the major vendor/key players in the market.

Detailed Segmentation:

By Product Type:Vector-based CasDNA-free CasGlobal CRISPR and CAS Gene Market, By Application:Genome EngineeringDisease modelsFunctional GenomicsKnockdown/activationOther Applications

Regions included:

o North America (United States, Canada, and Mexico)

o Europe (Germany, France, UK, Russia, and Italy)

o Asia-Pacific (China, Japan, Korea, India, and Southeast Asia)

o South America (Brazil, Argentina, Colombia)

o Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, and South Africa)

Key Benefits:

o This study gives a detailed analysis of drivers and factors limiting the market expansion of CRISPR and CAS Gene

o The micro-level analysis is conducted based on its product types, end-user applications, and geographies

o Porters five forces model gives an in-depth analysis of buyers and suppliers, threats of new entrants & substitutes and competition amongst the key market players

o By understanding the value chain analysis, the stakeholders can get a clear and detailed picture of this CRISPR and CAS Gene market

The PDF Research only provides Table of Contents (ToC), scope of the report and research framework of the report.

Get PDF brochure of this report: https://www.coherentmarketinsights.com/insight/request-pdf/2598

The research study can answer the following Key questions:

Table of Contents

Report Overview: It includes the CRISPR and CAS Gene market study scope, players covered, key market segments, market analysis by application, market analysis by type, and other chapters that give an overview of the research study.

Executive Summary: This section of the report gives information about CRISPR and CAS Gene market trends and shares, market size analysis by region and analysis of global market size. Under market size analysis by region, analysis of market share and growth rate by region is provided.

Profiles of International Players: Here, key players of the CRISPR and CAS Gene market are studied on the basis of gross margin, price, revenue, corporate sales, and production. This section gives a business overview of the players and shares their important company details.

Regional Study: All of the regions and countries analyzed in the CRISPR and CAS Gene market report is studied on the basis of market size by application, the market size by product, key players, and market forecast.

We Do Offer Sample of this report. Kindly go through the follow information in order to access the report.

Note- This report sample includes:

Brief Introduction to the research report.

Table of Contents (Scope covered as a part of the study)

Top players in the market

Research framework (presentation)

Research methodology adopted by CMI

Request sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/2598

An Overview of the Impact of COVID-19 on this Market:

The pandemic of COVID-19 continues to expand and impact over 175 countries and territories. Although the outbreak appears to have slowed in China, COVID-19 has impacted globally. The pandemic could affect three main aspects of the global economy: production, supply chain, and firms and financial markets. National governments have announced largely uncoordinated, country-specific responses to the virus. As authorities encourage social distancing and consumers stay indoors, several businesses are hit. However, coherent, coordinated, and credible policy responses are expected to offer the best chance at limiting the economic fallout.

National governments and international bodies are focused on adopting collaborative efforts to encourage financial institutions to meet the financial needs of customers and members affected by the coronavirus. However, there are some sectors that have remained unscathed from the impact of the pandemic and there are some that are hit the hardest.

Reasons to Purchase CRISPR and CAS Gene report is:

Gives a complete understanding of the CRISPR and CAS Gene Market to express competitor information, analysis, and insights to formulate effective RD strategies.

Collect data of the developing participants having the potentially profitable portfolio in this space and create effective counter-strategies to gain competitive benefits.

Note: Access insightful study with over 150+ pages, list of tables & figures, profiling 20+ companies.

Buy This Complete A Business Report: https://www.coherentmarketinsights.com/insight/buy-now/2598

Thanks For Reading This Article; You Can Also Get Individual Chapter Wise Section Or Region Wise Report Versions Like North America, Europe Or Southeast Asia Or Just Eastern Asia.

**Be Safe and Stay Home**

About Us:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contacts US:

Mr. ShahCoherent Market Insights,1001 4th Ave,#3200 Seattle, WA 98154, U.S.Email:sales@coherentmarketinsights.comPhone: US +1-206-701-6702/UK +44-020 8133 4027

Link:
CRISPR and CAS Gene Market to Witness Huge Growth by 2027 | Caribou Biosciences Inc., CRISPR Therapeutics, Mirus Bio LLC, Editas Medicine, Takara Bio...

The shares of CRISPR Therapeutics AG (NASDAQ:CRSP) has been pegged with a rating of Hold by Stifel in its latest research note that was published on March 05, 2020. The Healthcare company has also assigned a $52 price target. Stifel wasnt the only research firm that published a report of CRISPR Therapeutics AG, with other equities research analysts also giving their opinion on the stock. Evercore ISI advised investors in its research note published on February 03, 2020, to In-line the CRSP stock while also putting a $52 price target. The stock had earned Outperform rating from William Blair Markets when it published its report on November 19, 2019. The stock was given Outperform rating by Oppenheimer in its report released on November 12, 2019, the day when the price target on the stock was placed at 65. Jefferies was of a view that CRSP is Buy in its latest report on August 01, 2019. Canaccord Genuity thinks that CRSP is worth Buy rating. This was contained in the firms report on July 26, 2019 in which the stocks price target was also moved to 72.

Amongst the analysts that rated the stock, 2 have recommended investors to sell it, 4 believe it has the potential for further growth, thus rating it as Hold while 11 advised investors to purchase the stock. The price of the stock the last time has raised by 89.13% from its 52-Week high price while it is -17.45% than its 52-Week low price. A look at the stocks other technical shows that its 14-day RSI now stands at 66.89.

The shares of the company added by 9.32% during the trading session on Friday, reaching a low of $54.86 while ending the day at $61.09. During the trading session, a total of 1.03 million shares were traded which represents a -6.22% decline from the average session volume which is 0.97 million shares. CRSP had ended its last session trading at $55.88. CRISPR Therapeutics AG debt-to-equity ratio currently stands at 0.00, while its quick ratio hovers at 16.90 CRSP 52-week low price stands at $32.30 while its 52-week high price is $74.00.

The company in its last quarterly report recorded -$1.15 earnings per share which is below the predicted by most analysts. The CRISPR Therapeutics AG generated 889.71 million in revenue during the last quarter. In the second quarter last year, the firm recorded $0.51 earnings per share. Compared to the same quarter last year, the firms revenue was up by 12.17%. CRISPR Therapeutics AG has the potential to record -4.51 EPS for the current fiscal year, according to equities analysts.

Investment analysts at BofA/Merrill published a research note on May 15, 2020 where it informed investors and clients that Canada Goose Holdings Inc. (NYSE:GOOS) is now rated as Underperform. Even though the stock has been trading at $20.70/share, analysts expect it to down by -7.15% to reach $32.90/share. It started the day trading at $19.74 and traded between $18.52 and $19.22 throughout the trading session.

A look at its technical shows that GOOSs 50-day SMA is 20.58 while its 200-day SMA stands at 33.10. The stock has a high of $51.71 for the year while the low is $12.94. The stock, however, witnessed a rise in its short on 04/30/20. Compared to previous close which recorded 10.25 M shorted shares, the short percentage went lower by -6.05%, as 9.63M CRSP shares were shorted. At the moment, only 16.46% of Canada Goose Holdings Inc. shares were sold short. The companys P/E ratio currently sits at 28.14, while the P/B ratio is 9.99. The companys average trading volume currently stands at 2.23M shares, which means that the short-interest ratio is just 4.32 days. Over the past seven days, the company moved, with its shift of -15.74%. Looking further, the stock has dropped -38.00% over the past 90 days while it lost -44.79% over the last six months.

Morgan Stanley Asia Ltd. (Investm meanwhile bought more GOOS shares in the recently filed quarter, changing its stake to $162,992,259 worth of shares.

Following these latest developments, around 0.71% of Canada Goose Holdings Inc. stocks are owned by institutional investors and hedge funds.

Follow this link:
Mixed Analyst Attention: CRISPR Therapeutics AG (NASDAQ:CRSP), Canada Goose Holdings Inc. (NYSE:GOOS) - State Reviewer